drug1_db stringlengths 7 7 | drug2_db stringlengths 7 7 | drug1_id int64 0 1.69k | drug2_id int64 0 1.69k | drug_pair listlengths 2 2 | drug1_name stringlengths 4 85 | drug2_name stringlengths 4 85 | drug1_desc stringlengths 27 1.09k | drug2_desc stringlengths 27 6.14k | label stringclasses 3
values | label_idx int64 0 2 | all_paths listlengths 1 10 | all_paths_str listlengths 1 10 | path_str stringlengths 0 3.57k |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
DB00682 | DB01017 | 126 | 1,669 | [
"DDInter1951",
"DDInter1224"
] | Warfarin | Minocycline | Warfarin is an anticoagulant drug normally used to prevent blood clot formation as well as migration. Although originally marketed as a pesticide (d-Con, Rodex, among others), Warfarin has since become the most frequently prescribed oral anticoagulant in North America. Warfarin has several properties that should be not... | Minocycline was first described in the literacture in 1966. It is a second generation tetracycline antibiotic that is active against gram-negative and gram-positive bacteria. Like other semisynthetic tetracyclines, minocycline has modifications to carbons 7-9 on the D ring to generate higher efficacy than previous tetr... | Moderate | 1 | [
[
[
126,
24,
1669
]
],
[
[
126,
63,
1572
],
[
1572,
1,
1669
]
],
[
[
126,
63,
1545
],
[
1545,
40,
1669
]
],
[
[
126,
24,
1620
],
[
1620,
... | [
[
[
"Warfarin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Minocycline"
]
],
[
[
"Warfarin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Demeclocycline"
],
[
... | Warfarin may cause a moderate interaction that could exacerbate diseases when taken with Demeclocycline and Demeclocycline (Compound) resembles Minocycline (Compound)
Warfarin may cause a moderate interaction that could exacerbate diseases when taken with Oxytetracycline and Oxytetracycline (Compound) resembles Minocyc... |
DB00390 | DB01211 | 1,252 | 609 | [
"DDInter554",
"DDInter393"
] | Digoxin | Clarithromycin | Digoxin is one of the oldest cardiovascular medications used today. It is a common agent used to manage atrial fibrillation and the symptoms of heart failure. Digoxin is classified as a cardiac glycoside and was initially approved by the FDA in 1954. This drug originates from the foxglove plant, also known as the _Digi... | Clarithromycin, a semisynthetic macrolide antibiotic derived from erythromycin, inhibits bacterial protein synthesis by binding to the bacterial 50S ribosomal subunit. Binding inhibits peptidyl transferase activity and interferes with amino acid translocation during the translation and protein assembly process. Clarith... | Major | 2 | [
[
[
1252,
25,
609
]
],
[
[
1252,
6,
4973
],
[
4973,
45,
609
]
],
[
[
1252,
7,
4904
],
[
4904,
46,
609
]
],
[
[
1252,
18,
4360
],
[
4360,
... | [
[
[
"Digoxin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Clarithromycin"
]
],
[
[
"Digoxin",
"{u} (Compound) binds {v} (Gene)",
"ABCB1"
],
[
"ABCB1",
"{u} (Gene) is bound by {v} (Compound)",
"Clarithromy... | Digoxin (Compound) binds ABCB1 (Gene) and ABCB1 (Gene) is bound by Clarithromycin (Compound)
Digoxin (Compound) upregulates CNOT4 (Gene) and CNOT4 (Gene) is upregulated by Clarithromycin (Compound)
Digoxin (Compound) downregulates TIMM9 (Gene) and TIMM9 (Gene) is downregulated by Clarithromycin (Compound)
Digoxin (Comp... |
DB00393 | DB01254 | 854 | 1,213 | [
"DDInter1295",
"DDInter484"
] | Nimodipine | Dasatinib | Nimodipine is a 1,4-dihydropyridine calcium channel blocker. It acts primarily on vascular smooth muscle cells by stabilizing voltage-gated L-type calcium channels in their inactive conformation. By inhibiting the influx of calcium in smooth muscle cells, nimodipine prevents calcium-dependent smooth muscle contraction ... | Dasatinib is an orally available multikinase inhibitor indicated for the treatment of Philadelphia chromosome (Ph)-positive leukemias.[A2224,L45171] Ph is a chromosomal abnormality found in patients with chronic myelogenous leukemia (CML) and acute lymphocytic leukemia (ALL), where the ABL tyrosine kinase and the break... | Moderate | 1 | [
[
[
854,
24,
1213
]
],
[
[
854,
6,
8374
],
[
8374,
45,
1213
]
],
[
[
854,
21,
28956
],
[
28956,
60,
1213
]
],
[
[
854,
24,
1619
],
[
1619,... | [
[
[
"Nimodipine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dasatinib"
]
],
[
[
"Nimodipine",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compound)",
... | Nimodipine (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Dasatinib (Compound)
Nimodipine (Compound) causes Palpitations (Side Effect) and Palpitations (Side Effect) is caused by Dasatinib (Compound)
Nimodipine may cause a moderate interaction that could exacerbate diseases when taken with Rucaparib and R... |
DB00023 | DB01268 | 305 | 1,151 | [
"DDInter127",
"DDInter1731"
] | Asparaginase Escherichia coli | Sunitinib | Asparaginase derived from _Escherichia coli_ (L-asparagine amidohydrolase, EC 3.5.1.1) is an enzyme responsible for the metabolism of L-asparagine, by catalyzing L-asparagine into L-aspartic acid and ammonia. It also facilitates the production of oxaloacetate which is needed for general cellular metabolism. Asparaginas... | Sunitinib is a small-molecule multi-targeted receptor tyrosine kinase (RTK) inhibitor. On January 26, 2006, the agent was formally approved by the US FDA for the indications of treating renal cell carcinoma (RCC) and imatinib-resistant gastrointestinal stromal tumor (GIST). For these purposes, sunitinib is generally av... | Moderate | 1 | [
[
[
305,
24,
1151
]
],
[
[
305,
24,
1247
],
[
1247,
23,
1151
]
],
[
[
305,
24,
1250
],
[
1250,
63,
1151
]
],
[
[
305,
24,
847
],
[
847,
... | [
[
[
"Asparaginase Escherichia coli",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sunitinib"
]
],
[
[
"Asparaginase Escherichia coli",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}... | Asparaginase Escherichia coli may cause a moderate interaction that could exacerbate diseases when taken with Sulfamethoxazole and Sulfamethoxazole may cause a minor interaction that can limit clinical effects when taken with Sunitinib
Asparaginase Escherichia coli may cause a moderate interaction that could exacerbate... |
DB00812 | DB09122 | 998 | 1,613 | [
"DDInter1451",
"DDInter1409"
] | Phenylbutazone | Peginterferon beta-1a | A drug that has anti-inflammatory, antipyretic, and analgesic activities. It is especially effective in the treatment of ankylosing spondylitis. It also is useful in rheumatoid arthritis and Reiter's syndrome (investigational indication). Although phenylbutazone is effective in gouty arthritis, risk/benefit conside... | Multiple Sclerosis (MS) is a chronic and inflammatory autoimmune disease of the central nervous system, disrupting communication between the brain and other parts of the body. Most patients diagnosed with this illness experience their initial disease symptoms between the age of 20 to 40, often the most productive years... | Moderate | 1 | [
[
[
998,
24,
1613
]
],
[
[
998,
62,
168
],
[
168,
24,
1613
]
],
[
[
998,
63,
1274
],
[
1274,
24,
1613
]
],
[
[
998,
1,
651
],
[
651,
... | [
[
[
"Phenylbutazone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Peginterferon beta-1a"
]
],
[
[
"Phenylbutazone",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Bortezomib... | Phenylbutazone may cause a minor interaction that can limit clinical effects when taken with Bortezomib and Bortezomib may cause a moderate interaction that could exacerbate diseases when taken with Peginterferon beta-1a
Phenylbutazone may cause a moderate interaction that could exacerbate diseases when taken with Flur... |
DB00524 | DB11113 | 811 | 657 | [
"DDInter1199",
"DDInter307"
] | Metolazone | Castor oil | A quinazoline-sulfonamide that is considered a thiazide-like diuretic which is long-acting so useful in chronic renal failure. It also tends to lower blood pressure and increase potassium loss. | Castor oil is a vegetable oil obtained by pressing the seeds of the castor oil plant (_Ricinus communis_ L.) mainly cultivated in India, South America, Africa, and China. Castor oil is a rich source of , which represents up to 90% of the total castor oil content. It also consists up to 4% linoleic, 3% oleic, 1% stearic... | Moderate | 1 | [
[
[
811,
24,
657
]
],
[
[
811,
24,
891
],
[
891,
24,
657
]
],
[
[
811,
24,
1019
],
[
1019,
63,
657
]
],
[
[
811,
1,
1605
],
[
1605,
... | [
[
[
"Metolazone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Castor oil"
]
],
[
[
"Metolazone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Prednisolone"
],
[
... | Metolazone may cause a moderate interaction that could exacerbate diseases when taken with Prednisolone and Prednisolone may cause a moderate interaction that could exacerbate diseases when taken with Castor oil
Metolazone may cause a moderate interaction that could exacerbate diseases when taken with Deflazacort and D... |
DB00855 | DB01259 | 213 | 392 | [
"DDInter72",
"DDInter1024"
] | Aminolevulinic acid | Lapatinib | A compound produced from succinyl-CoA and glycine as an intermediate in heme synthesis. It is used as a photochemotherapy for actinic keratosis. [PubChem] | Lapatinib is an anti-cancer drug developed by GlaxoSmithKline (GSK) as a treatment for solid tumours such as breast and lung cancer. It was approved by the FDA on March 13, 2007, for use in patients with advanced metastatic breast cancer in conjunction with the chemotherapy drug capecitabine. Lapatinib is a human epide... | Major | 2 | [
[
[
213,
25,
392
]
],
[
[
213,
21,
29429
],
[
29429,
60,
392
]
],
[
[
213,
25,
1247
],
[
1247,
23,
392
]
],
[
[
213,
25,
918
],
[
918,
... | [
[
[
"Aminolevulinic acid",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Lapatinib"
]
],
[
[
"Aminolevulinic acid",
"{u} (Compound) causes {v} (Side Effect)",
"Infestation NOS"
],
[
"Infestation NOS",
"{u} (Side E... | Aminolevulinic acid (Compound) causes Infestation NOS (Side Effect) and Infestation NOS (Side Effect) is caused by Lapatinib (Compound)
Aminolevulinic acid may lead to a major life threatening interaction when taken with Sulfamethoxazole and Sulfamethoxazole may cause a minor interaction that can limit clinical effects... |
DB00197 | DB01254 | 1,324 | 1,213 | [
"DDInter1881",
"DDInter484"
] | Troglitazone | Dasatinib | Troglitazone was withdrawn in 2000 due to risk of hepatotoxicity. It was superseded by [pioglitazone] and [rosiglitazone]. | Dasatinib is an orally available multikinase inhibitor indicated for the treatment of Philadelphia chromosome (Ph)-positive leukemias.[A2224,L45171] Ph is a chromosomal abnormality found in patients with chronic myelogenous leukemia (CML) and acute lymphocytic leukemia (ALL), where the ABL tyrosine kinase and the break... | Moderate | 1 | [
[
[
1324,
24,
1213
]
],
[
[
1324,
24,
907
],
[
907,
62,
1213
]
],
[
[
1324,
24,
479
],
[
479,
23,
1213
]
],
[
[
1324,
23,
1459
],
[
1459,
... | [
[
[
"Troglitazone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dasatinib"
]
],
[
[
"Troglitazone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Doravirine"
],
[... | Troglitazone may cause a moderate interaction that could exacerbate diseases when taken with Doravirine and Doravirine may cause a minor interaction that can limit clinical effects when taken with Dasatinib
Troglitazone may cause a moderate interaction that could exacerbate diseases when taken with Donepezil and Donepe... |
DB00674 | DB09330 | 1,516 | 985 | [
"DDInter802",
"DDInter1352"
] | Galantamine | Osimertinib | Galantamine is a tertiary alkaloid and reversible, competitive inhibitor of the acetylcholinesterase (AChE) enzyme, which is a widely studied therapeutic target used in the treatment of Alzheimer's disease. First characterized in the early 1950s, galantamine is a tertiary alkaloid that was extracted from botanical sour... | Osimertinib is an oral, third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) drug developed by AstraZeneca Pharmaceuticals.[A7926,L43453] Its use is indicated for the treatment of metastatic non-small cell lung cancer (NSCLC) in cases where tumour EGFR expression is positive for the ... | Moderate | 1 | [
[
[
1516,
24,
985
]
],
[
[
1516,
24,
112
],
[
112,
23,
985
]
],
[
[
1516,
63,
1181
],
[
1181,
24,
985
]
],
[
[
1516,
24,
283
],
[
283,
... | [
[
[
"Galantamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Osimertinib"
]
],
[
[
"Galantamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Metronidazole"
],
... | Galantamine may cause a moderate interaction that could exacerbate diseases when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Osimertinib
Galantamine may cause a moderate interaction that could exacerbate diseases when taken with Terfenadine an... |
DB08865 | DB11652 | 1,593 | 1,155 | [
"DDInter448",
"DDInter1891"
] | Crizotinib | Tucatinib | Crizotinib is a tyrosine kinase receptor inhibitor used for the treatment of anaplastic lymphoma kinase (ALK) or ROS1-positive non-small cell lung cancer (NSCLC) tumors, as well as ALK-positive anaplastic large cell lymphoma (ALCL) and inflammatory myofibroblastic tumor (IMT). By targeting the echinoderm microtubule-as... | Tucatinib is a kinase inhibitor drug used with [trastuzumab] and [capecitabine] in the treatment of unresectable or metastatic HER-2 positive breast cancer. It was developed by Seattle Genetics and approved by the FDA on April 17, 2020. Tucatinib is a promising new treatment for patients with metastatic breast cancer w... | Major | 2 | [
[
[
1593,
25,
1155
]
],
[
[
1593,
63,
1101
],
[
1101,
23,
1155
]
],
[
[
1593,
64,
1424
],
[
1424,
24,
1155
]
],
[
[
1593,
24,
659
],
[
659... | [
[
[
"Crizotinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Tucatinib"
]
],
[
[
"Crizotinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bexarotene"
],
[
"Bexarotene"... | Crizotinib may cause a moderate interaction that could exacerbate diseases when taken with Bexarotene and Bexarotene may cause a minor interaction that can limit clinical effects when taken with Tucatinib
Crizotinib may lead to a major life threatening interaction when taken with Quinine and Quinine may cause a moderat... |
DB01015 | DB01211 | 1,247 | 609 | [
"DDInter1724",
"DDInter393"
] | Sulfamethoxazole | Clarithromycin | Sulfamethoxazole is a bacteriostatic sulfonamide antibiotic that interferes with folic acid synthesis in susceptible bacteria. It is generally given in combination with [trimethoprim], which inhibits a sequential step in bacterial folic acid synthesis - these agents work synergistically to block two consecutive steps i... | Clarithromycin, a semisynthetic macrolide antibiotic derived from erythromycin, inhibits bacterial protein synthesis by binding to the bacterial 50S ribosomal subunit. Binding inhibits peptidyl transferase activity and interferes with amino acid translocation during the translation and protein assembly process. Clarith... | Minor | 0 | [
[
[
1247,
23,
609
]
],
[
[
1247,
6,
8374
],
[
8374,
45,
609
]
],
[
[
1247,
18,
10375
],
[
10375,
57,
609
]
],
[
[
1247,
21,
28759
],
[
287... | [
[
[
"Sulfamethoxazole",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Clarithromycin"
]
],
[
[
"Sulfamethoxazole",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v... | Sulfamethoxazole (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Clarithromycin (Compound)
Sulfamethoxazole (Compound) downregulates RPS4Y1 (Gene) and RPS4Y1 (Gene) is downregulated by Clarithromycin (Compound)
Sulfamethoxazole (Compound) causes Connective tissue disorder (Side Effect) and Connective tissu... |
DB01175 | DB12332 | 318 | 1,619 | [
"DDInter672",
"DDInter1626"
] | Escitalopram | Rucaparib | Escitalopram is a selective serotonin re-uptake inhibitor (SSRI) and the S-enantiomer of racemic [citalopram]. It is used to restore serotonergic function in the treatment of depression and anxiety.[L8513,L8516,L8522] Escitalopram is approximately 150 times more potent than citalopram’s R-enantiomer and is responsible ... | Rucaparib is an anticancer drug and poly (ADP-ribose) polymerase (PARP) inhibitor. PARP is an enzyme that plays an essential role in DNA repair. Rucaparib is proposed to work in several PARP-dependent and PARP-independent mechanisms of action; however, it causes a unique effect of synthetic lethality. By targeting the ... | Major | 2 | [
[
[
318,
25,
1619
]
],
[
[
318,
64,
222
],
[
222,
23,
1619
]
],
[
[
318,
62,
112
],
[
112,
23,
1619
]
],
[
[
318,
24,
1662
],
[
1662,
... | [
[
[
"Escitalopram",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Rucaparib"
]
],
[
[
"Escitalopram",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Sibutramine"
],
[
"Sibutramine",
"... | Escitalopram may lead to a major life threatening interaction when taken with Sibutramine and Sibutramine may cause a minor interaction that can limit clinical effects when taken with Rucaparib
Escitalopram may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may... |
DB00515 | DB00877 | 589 | 629 | [
"DDInter387",
"DDInter1678"
] | Cisplatin | Sirolimus | Cisplatin, cisplatinum or cis-diamminedichloroplatinum(II) (CDDP) is a platinum-based chemotherapy drug used to treat various types of cancers, including sarcomas, some carcinomas (e.g. small cell lung cancer, and ovarian cancer), lymphomas and germ cell tumors. It was the first member of its class, which now also incl... | Sirolimus, also known as rapamycin, is a macrocyclic lactone antibiotic produced by bacteria _Streptomyces hygroscopicus_, which was isolated from the soil of the Vai Atari region of Rapa Nui (Easter Island). It was first isolated and identified as an antifungal agent with potent anticandida activity; however, after it... | Major | 2 | [
[
[
589,
25,
629
]
],
[
[
589,
6,
4973
],
[
4973,
45,
629
]
],
[
[
589,
6,
8155
],
[
8155,
46,
629
]
],
[
[
589,
21,
29203
],
[
29203,
... | [
[
[
"Cisplatin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Sirolimus"
]
],
[
[
"Cisplatin",
"{u} (Compound) binds {v} (Gene)",
"ABCB1"
],
[
"ABCB1",
"{u} (Gene) is bound by {v} (Compound)",
"Sirolimus"
... | Cisplatin (Compound) binds ABCB1 (Gene) and ABCB1 (Gene) is bound by Sirolimus (Compound)
Cisplatin (Compound) binds ABCC5 (Gene) and ABCC5 (Gene) is upregulated by Sirolimus (Compound)
Cisplatin (Compound) causes Aspartate aminotransferase increased (Side Effect) and Aspartate aminotransferase increased (Side Effect) ... |
DB01115 | DB01246 | 336 | 820 | [
"DDInter1291",
"DDInter45"
] | Nifedipine | Alimemazine | Nifedipine, or BAY a 1040, is a first generation dihydropyridine L-type calcium channel blocker, similar to [nicardipine].[A190210,A190273,A175390,L11383] Nifedipine was developed by Bayer and first described in the literature, along with other dihydropyridines, in 1972.[A175390,A190276] Since nifedipine's development,... | A phenothiazine derivative that is used as an antipruritic. | Moderate | 1 | [
[
[
336,
24,
820
]
],
[
[
336,
63,
104
],
[
104,
40,
820
]
],
[
[
336,
63,
401
],
[
401,
24,
820
]
],
[
[
336,
6,
8374
],
[
8374,
45... | [
[
[
"Nifedipine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Alimemazine"
]
],
[
[
"Nifedipine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Methdilazine"
],
[... | Nifedipine may cause a moderate interaction that could exacerbate diseases when taken with Methdilazine and Methdilazine (Compound) resembles Alimemazine (Compound)
Nifedipine may cause a moderate interaction that could exacerbate diseases when taken with Promethazine and Promethazine may cause a moderate interaction t... |
DB00041 | DB11793 | 1,648 | 738 | [
"DDInter38",
"DDInter1297"
] | Aldesleukin | Niraparib | Aldesleukin, a lymphokine, is produced by recombinant DNA technology using a genetically engineered E. coli strain containing an analog of the human interleukin-2 gene. Genetic engineering techniques were used to modify the human IL-2 gene, and the resulting expression clone encodes a modified human interleukin-2. This... | Niraparib is an orally active poly (ADP-ribose) polymerase (PARP) inhibitor. By blocking the enzymes responsible for DNA repair, niraparib induces cytotoxicity in cancer cells. Niraparib is selective towards PARP-1 and PARP-2. First approved by the FDA on March 27, 2017, niraparib is used to treat epithelial ovarian, f... | Moderate | 1 | [
[
[
1648,
24,
738
]
],
[
[
1648,
24,
663
],
[
663,
24,
738
]
],
[
[
1648,
63,
1253
],
[
1253,
24,
738
]
],
[
[
1648,
25,
589
],
[
589,
... | [
[
[
"Aldesleukin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Niraparib"
]
],
[
[
"Aldesleukin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Methotrexate"
],
[... | Aldesleukin may cause a moderate interaction that could exacerbate diseases when taken with Methotrexate and Methotrexate may cause a moderate interaction that could exacerbate diseases when taken with Niraparib
Aldesleukin may cause a moderate interaction that could exacerbate diseases when taken with Palifermin and P... |
DB01001 | DB08875 | 688 | 1,618 | [
"DDInter1632",
"DDInter262"
] | Salbutamol | Cabozantinib | Salbutamol is a short-acting, selective beta2-adrenergic receptor agonist used in the treatment of asthma and COPD. It is 29 times more selective for beta2 receptors than beta1 receptors giving it higher specificity for pulmonary beta receptors versus beta1-adrenergic receptors located in the heart. Salbutamol is formu... | Cabozantinib was first approved in 2012 and is a non-specific tyrosine kinase inhibitor. It was initially approved in the US under the brand name Cometriq, which is indicated for the treatment of metastatic medullary thyroid cancer. In 2016, a capsule formulation (Cabometyx) was approved for the treatment of advanced r... | Moderate | 1 | [
[
[
688,
24,
1618
]
],
[
[
688,
62,
112
],
[
112,
23,
1618
]
],
[
[
688,
23,
1247
],
[
1247,
23,
1618
]
],
[
[
688,
63,
307
],
[
307,
... | [
[
[
"Salbutamol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cabozantinib"
]
],
[
[
"Salbutamol",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Metronidazole"
],
[... | Salbutamol may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Cabozantinib
Salbutamol may cause a minor interaction that can limit clinical effects when taken with Sulfamethoxazole an... |
DB00218 | DB01229 | 1,176 | 973 | [
"DDInter1247",
"DDInter1378"
] | Moxifloxacin | Paclitaxel (protein-bound) | Moxifloxacin is a synthetic fluoroquinolone antibiotic agent. Bayer AG developed the drug (initially called BAY 12-8039) and it is marketed worldwide (as the hydrochloride) under the brand name Avelox (in some countries also Avalox) for oral treatment. | Paclitaxel can cause developmental toxicity, female reproductive toxicity and male reproductive toxicity according to state or federal government labeling requirements. | Minor | 0 | [
[
[
1176,
23,
973
]
],
[
[
1176,
6,
3199
],
[
3199,
57,
973
]
],
[
[
1176,
21,
29267
],
[
29267,
60,
973
]
],
[
[
1176,
1,
945
],
[
945,
... | [
[
[
"Moxifloxacin",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Paclitaxel"
]
],
[
[
"Moxifloxacin",
"{u} (Compound) binds {v} (Gene)",
"TOP2A"
],
[
"TOP2A",
"{u} (Gene) is downregulated by {v} (Com... | Moxifloxacin may cause a minor interaction that can limit clinical effects when taken with Paclitaxel
Moxifloxacin (Compound) binds TOP2A (Gene) and TOP2A (Gene) is downregulated by Paclitaxel (Compound)
Moxifloxacin (Compound) causes Alanine aminotransferase increased (Side Effect) and Alanine aminotransferase increas... |
DB01175 | DB12364 | 318 | 1,421 | [
"DDInter672",
"DDInter200"
] | Escitalopram | Betrixaban | Escitalopram is a selective serotonin re-uptake inhibitor (SSRI) and the S-enantiomer of racemic [citalopram]. It is used to restore serotonergic function in the treatment of depression and anxiety.[L8513,L8516,L8522] Escitalopram is approximately 150 times more potent than citalopram’s R-enantiomer and is responsible ... | Betrixaban is a non-vitamin K oral anticoagulant whose action is driven by the competitive and reversible inhibition of the factor Xa . It was selected among all lead compounds due to its low hERG channel affinity while sustaining its factor Xa inhibition capacity . Betrixaban, now developed by Portola Pharmaceuticals ... | Moderate | 1 | [
[
[
318,
24,
1421
]
],
[
[
318,
24,
1017
],
[
1017,
24,
1421
]
],
[
[
318,
25,
1151
],
[
1151,
24,
1421
]
],
[
[
318,
23,
760
],
[
760,
... | [
[
[
"Escitalopram",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Betrixaban"
]
],
[
[
"Escitalopram",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lorlatinib"
],
... | Escitalopram may cause a moderate interaction that could exacerbate diseases when taken with Lorlatinib and Lorlatinib may cause a moderate interaction that could exacerbate diseases when taken with Betrixaban
Escitalopram may lead to a major life threatening interaction when taken with Sunitinib and Sunitinib may caus... |
DB00285 | DB00889 | 1,100 | 1,133 | [
"DDInter1927",
"DDInter840"
] | Venlafaxine | Granisetron | Venlafaxine is an antidepressant and a serotonin and norepinephrine reuptake inhibitor (SNRI). Its active metabolite, [desvenlafaxine], works by blocking the reuptake of serotonin and norepinephrine, which are key neurotransmitters in mood regulation. Venlafaxine is officially approved to treat major depressive disorde... | A serotonin receptor (5HT-3 selective) antagonist that has been used as an antiemetic and antinauseant for cancer chemotherapy patients. | Major | 2 | [
[
[
1100,
25,
1133
]
],
[
[
1100,
6,
8374
],
[
8374,
45,
1133
]
],
[
[
1100,
21,
29282
],
[
29282,
60,
1133
]
],
[
[
1100,
23,
112
],
[
11... | [
[
[
"Venlafaxine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Granisetron"
]
],
[
[
"Venlafaxine",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compound)",
"Gran... | Venlafaxine (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Granisetron (Compound)
Venlafaxine (Compound) causes Arrhythmia (Side Effect) and Arrhythmia (Side Effect) is caused by Granisetron (Compound)
Venlafaxine may cause a minor interaction that can limit clinical effects when taken with Metronidazole ... |
DB05812 | DB14761 | 1,374 | 242 | [
"DDInter8",
"DDInter1578"
] | Abiraterone | Remdesivir | Abiraterone is a potent, irreversible, and selective inhibitor of 17 αhydroxylase/C17,20-lyase (CYP17), an enzyme expressed in testicular, adrenal, and prostatic tumour tissues, to regulate androgen biosynthesis.[A3811, A260880, L40968] Abiraterone was first approved by the FDA and EMA on April, July, and September 201... | Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the causative agent of coronavirus disease 2019 (COVID-19), which is a respiratory disease that is capable of progressing to viral pneumonia and acute respiratory distress syndrome (ARDS); COVID-19 can be fatal. Like other RNA viruses, SARS-CoV-2 depends o... | Moderate | 1 | [
[
[
1374,
24,
242
]
],
[
[
1374,
63,
1130
],
[
1130,
24,
242
]
],
[
[
1374,
64,
1377
],
[
1377,
24,
242
]
],
[
[
1374,
25,
129
],
[
129,
... | [
[
[
"Abiraterone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Remdesivir"
]
],
[
[
"Abiraterone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pioglitazone"
],
... | Abiraterone may cause a moderate interaction that could exacerbate diseases when taken with Pioglitazone and Pioglitazone may cause a moderate interaction that could exacerbate diseases when taken with Remdesivir
Abiraterone may lead to a major life threatening interaction when taken with Leflunomide and Leflunomide ma... |
DB00470 | DB00777 | 530 | 146 | [
"DDInter601",
"DDInter1537"
] | Dronabinol | Propiomazine | Dronabinol (marketed as Marinol) is a synthetic form of delta-9-tetrahydrocannabinol (Δ⁹-THC), the primary psychoactive component of cannabis (marijuana). THC demonstrates its effects through weak partial agonist activity at Cannabinoid-1 (CB1R) and Cannabinoid-2 (CB2R) receptors, which results in the well-known effect... | Propiomazine, an atypical antipsychotic agent, is used to treat both negative and positive symptoms of schizophrenia, acute mania with bipolar disorder, agitation, and psychotic symptoms in dementia. Future uses may include the treatment of obsessive-compulsive disorder and severe behavioral disorders in autism. Struct... | Moderate | 1 | [
[
[
530,
24,
146
]
],
[
[
530,
63,
508
],
[
508,
1,
146
]
],
[
[
530,
24,
401
],
[
401,
63,
146
]
],
[
[
530,
24,
1178
],
[
1178,
1,... | [
[
[
"Dronabinol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Propiomazine"
]
],
[
[
"Dronabinol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Promazine"
],
[
... | Dronabinol may cause a moderate interaction that could exacerbate diseases when taken with Promazine and Promazine (Compound) resembles Propiomazine (Compound)
Dronabinol may cause a moderate interaction that could exacerbate diseases when taken with Promethazine and Promethazine may cause a moderate interaction that c... |
DB00549 | DB00916 | 522 | 112 | [
"DDInter1955",
"DDInter1202"
] | Zafirlukast | Metronidazole | Zafirlukast is an oral leukotriene receptor antagonist (LTRA) for the maintenance treatment of asthma, often used in conjunction with an inhaled steroid and/or long-acting bronchodilator. It is available as a tablet and is usually dosed twice daily. Another leukotriene receptor antagonist is montelukast (Singulair), wh... | Metronidazole is a commonly used antibiotic, belonging to the nitroimidazole class of antibiotics. It is frequently used to treat gastrointestinal infections as well as trichomoniasis and giardiasis, and amebiasis which are parasitic infections.[A181036,A181039] Metronidazole has been used as an antibiotic for several ... | Moderate | 1 | [
[
[
522,
24,
112
]
],
[
[
522,
24,
458
],
[
458,
40,
112
]
],
[
[
522,
6,
3486
],
[
3486,
45,
112
]
],
[
[
522,
21,
28757
],
[
28757,
... | [
[
[
"Zafirlukast",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Metronidazole"
]
],
[
[
"Zafirlukast",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tinidazole"
],
... | Zafirlukast may cause a moderate interaction that could exacerbate diseases when taken with Tinidazole and Tinidazole (Compound) resembles Metronidazole (Compound)
Zafirlukast (Compound) binds CYP2C8 (Gene) and CYP2C8 (Gene) is bound by Metronidazole (Compound)
Zafirlukast (Compound) causes Dyspepsia (Side Effect) and ... |
DB00004 | DB00005 | 669 | 1,057 | [
"DDInter499",
"DDInter687"
] | Denileukin diftitox | Etanercept | A recombinant DNA-derived cytotoxic protein composed of the amino acid sequences for diphtheria toxin fragments A and B (Met 1-Thr 387)-His followed by the sequences for interleukin-2 (IL-2; Ala 1-Thr 133). It is produced in an E. coli expression system. | Dimeric fusion protein consisting of the extracellular ligand-binding portion of the human 75 kilodalton (p75) tumor necrosis factor receptor (TNFR) linked to the Fc portion of human IgG1.[L14862,A216522] The Fc component of etanercept contains the CH2 domain, the CH3 domain and hinge region, but not the CH1 domain of ... | Major | 2 | [
[
[
669,
25,
1057
]
],
[
[
669,
24,
1129
],
[
1129,
63,
1057
]
],
[
[
669,
25,
962
],
[
962,
64,
1057
]
],
[
[
669,
24,
1184
],
[
1184,
... | [
[
[
"Denileukin diftitox",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Etanercept"
]
],
[
[
"Denileukin diftitox",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Human adenovirus e serot... | Denileukin diftitox may cause a moderate interaction that could exacerbate diseases when taken with Human adenovirus e serotype 4 strain cl-68578 antigen and Human adenovirus e serotype 4 strain cl-68578 antigen may cause a moderate interaction that could exacerbate diseases when taken with Etanercept
Denileukin diftit... |
DB00215 | DB00405 | 1,230 | 128 | [
"DDInter388",
"DDInter517"
] | Citalopram | Dexbrompheniramine | Citalopram is an antidepressant belonging to the class of selective _serotonin-reuptake inhibitors_ (SSRIs) widely used to treat the symptoms of depression. It is a racemic bicyclic phthalate derivate and is the only compound with a tertiary amine and 2 nitrogen-containing metabolites among all SSRIs.[A261316,A14720] C... | Dexbrompheniramine maleate is an antihistamine agent that is used for the treatment of allergic conditions, such as hay fever or urticaria. | Moderate | 1 | [
[
[
1230,
24,
128
]
],
[
[
1230,
24,
662
],
[
662,
63,
128
]
],
[
[
1230,
24,
28
],
[
28,
1,
128
]
],
[
[
1230,
6,
10104
],
[
10104,
... | [
[
[
"Citalopram",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dexbrompheniramine"
]
],
[
[
"Citalopram",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Carbinoxamine"
... | Citalopram may cause a moderate interaction that could exacerbate diseases when taken with Carbinoxamine and Carbinoxamine may cause a moderate interaction that could exacerbate diseases when taken with Dexbrompheniramine
Citalopram may cause a moderate interaction that could exacerbate diseases when taken with Bisacod... |
DB00758 | DB00844 | 1,347 | 314 | [
"DDInter413",
"DDInter1257"
] | Clopidogrel | Nalbuphine | Clopidogrel is a prodrug of a platelet inhibitor used to reduce the risk of myocardial infarction and stroke.[A180508,L7213] Clopidogrel is indicated to reduce the risk of myocardial infarction for patients with non-ST elevated acute coronary syndrome (ACS), patients with ST-elevated myocardial infarction, and in recen... | A narcotic used as a pain medication. It appears to be an agonist at kappa opioid receptors and an antagonist or partial agonist at mu opioid receptors. Nalbuphine is the only opioid analgesic that is not a controlled substance in the United States. | Moderate | 1 | [
[
[
1347,
24,
314
]
],
[
[
1347,
63,
828
],
[
828,
40,
314
]
],
[
[
1347,
63,
421
],
[
421,
1,
314
]
],
[
[
1347,
63,
475
],
[
475,
... | [
[
[
"Clopidogrel",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Nalbuphine"
]
],
[
[
"Clopidogrel",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Oxycodone"
],
[
... | Clopidogrel may cause a moderate interaction that could exacerbate diseases when taken with Oxycodone and Oxycodone (Compound) resembles Nalbuphine (Compound)
Clopidogrel may cause a moderate interaction that could exacerbate diseases when taken with Hydromorphone and Hydromorphone (Compound) resembles Nalbuphine (Comp... |
DB00365 | DB00938 | 839 | 455 | [
"DDInter842",
"DDInter1635"
] | Grepafloxacin | Salmeterol | Grepafloxacin is an oral broad-spectrum quinoline antibacterial agent used to treat bacterial infections. Due to the QTc-prolonging potential, as indicated by the changes in the QT interval on the electrocardiogram, and the risk for cardiovascular adverse events, grepafloxacin was withdrawn in the United States. | Salmeterol is a long-acting beta-2 adrenergic receptor agonist drug that is currently prescribed for the treatment of asthma and chronic obstructive pulmonary disease COPD.[L11545,L11548,L11551,L11554,L11557] It has a longer duration of action than the short-acting beta-2 adrenergic receptor agonist, [salbutamol]. Salm... | Moderate | 1 | [
[
[
839,
24,
455
]
],
[
[
839,
24,
688
],
[
688,
63,
455
]
],
[
[
839,
25,
167
],
[
167,
23,
455
]
],
[
[
839,
25,
1220
],
[
1220,
6... | [
[
[
"Grepafloxacin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Salmeterol"
]
],
[
[
"Grepafloxacin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Salbutamol"
],
... | Grepafloxacin may cause a moderate interaction that could exacerbate diseases when taken with Salbutamol and Salbutamol may cause a moderate interaction that could exacerbate diseases when taken with Salmeterol
Grepafloxacin may lead to a major life threatening interaction when taken with Hydrocortisone and Hydrocortis... |
DB01229 | DB01394 | 973 | 1,554 | [
"DDInter1377",
"DDInter431"
] | Paclitaxel | Colchicine | Paclitaxel is a chemotherapeutic agent marketed under the brand name Taxol among others. Used as a treatment for various cancers, paclitaxel is a mitotic inhibitor that was first isolated in 1971 from the bark of the Pacific yew tree which contains endophytic fungi that synthesize paclitaxel. It is available as an intr... | Colchicine is an alkaloid drug derived from a plant belonging to the Lily family, known as _Colchicum autumnale_, or "autumn crocus." Its use was first approved by the FDA in 1961. Colchicine is used in the treatment of gout flares and Familial Mediterranean fever, and prevention of major cardiovascular events. It has ... | Moderate | 1 | [
[
[
973,
24,
1554
]
],
[
[
973,
6,
3486
],
[
3486,
45,
1554
]
],
[
[
973,
34,
16974
],
[
16974,
46,
1554
]
],
[
[
973,
7,
10699
],
[
10699... | [
[
[
"Paclitaxel",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Colchicine"
]
],
[
[
"Paclitaxel",
"{u} (Compound) binds {v} (Gene)",
"CYP2C8"
],
[
"CYP2C8",
"{u} (Gene) is bound by {v} (Compound)",... | Paclitaxel (Compound) binds CYP2C8 (Gene) and CYP2C8 (Gene) is bound by Colchicine (Compound)
Paclitaxel (Compound) binds TUBB6 (Gene) and Paclitaxel (Compound) upregulates TUBB6 (Gene) and TUBB6 (Gene) is upregulated by Colchicine (Compound)
Paclitaxel (Compound) upregulates KIF20A (Gene) and KIF20A (Gene) is upregula... |
DB01611 | DB11652 | 1,487 | 1,155 | [
"DDInter893",
"DDInter1891"
] | Hydroxychloroquine | Tucatinib | Hydroxychloroquine is a racemic mixture consisting of an R and S enantiomer. Hydroxychloroquine is an aminoquinoline like [chloroquine]. It is a commonly prescribed medication in the treatment of uncomplicated malaria, rheumatoid arthritis, chronic discoid lupus erythematosus, and systemic lupus erythematosus. Hydroxyc... | Tucatinib is a kinase inhibitor drug used with [trastuzumab] and [capecitabine] in the treatment of unresectable or metastatic HER-2 positive breast cancer. It was developed by Seattle Genetics and approved by the FDA on April 17, 2020. Tucatinib is a promising new treatment for patients with metastatic breast cancer w... | Moderate | 1 | [
[
[
1487,
24,
1155
]
],
[
[
1487,
64,
1424
],
[
1424,
24,
1155
]
],
[
[
1487,
24,
659
],
[
659,
24,
1155
]
],
[
[
1487,
63,
522
],
[
522,
... | [
[
[
"Hydroxychloroquine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tucatinib"
]
],
[
[
"Hydroxychloroquine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Quinine"
],
[
... | Hydroxychloroquine may lead to a major life threatening interaction when taken with Quinine and Quinine may cause a moderate interaction that could exacerbate diseases when taken with Tucatinib
Hydroxychloroquine may cause a moderate interaction that could exacerbate diseases when taken with Vilanterol and Vilanterol m... |
DB00013 | DB06209 | 1,255 | 256 | [
"DDInter1905",
"DDInter1508"
] | Urokinase | Prasugrel | Urokinase is an endogenous peptide that is cleaved in the presence of plasmin between lysine 158 and isoleucine 159 to yield active urokinase. Urokinase remains connected between these 2 chains by a sulfhydryl bond. Urokinase was granted FDA approval on 16 January 1978. | Prasugrel, a thienopyridine derivative, is a platelet activation and aggregation inhibitor structurally and pharmacologically related to clopidogrel and ticlopidine. Similar to clopidogrel, prasugrel is a prodrug that requires enzymatic transformation in the liver to its active metabolite, R-138727. R-138727 irreversib... | Major | 2 | [
[
[
1255,
25,
256
]
],
[
[
1255,
23,
944
],
[
944,
62,
256
]
],
[
[
1255,
24,
901
],
[
901,
24,
256
]
],
[
[
1255,
24,
1427
],
[
1427,
... | [
[
[
"Urokinase",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Prasugrel"
]
],
[
[
"Urokinase",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Chamomile"
],
[
"Chamomile",
... | Urokinase may cause a minor interaction that can limit clinical effects when taken with Chamomile and Chamomile may cause a minor interaction that can limit clinical effects when taken with Prasugrel
Urokinase may cause a moderate interaction that could exacerbate diseases when taken with Milnacipran and Milnacipran ma... |
DB06204 | DB06764 | 768 | 1,090 | [
"DDInter1746",
"DDInter1788"
] | Tapentadol | Tetryzoline (ophthalmic) | Tapentadol is a centrally-acting synthetic analgesic with a dual mechanism of action. It is a mu-opioid receptor agonist that also inhibits norepinephrine reuptake.[A260721, A36596] Tapentadol was first approved by the FDA on November 20, 2008. The extended-release formulation of tapentadol was also approved by the FDA... | Tetryzoline is a member of imidazolines and a carboxamidine. It has a role as a sympathomimetic agent and a nasal decongestant. It is a conjugate base of a tetryzoline(1+). | Moderate | 1 | [
[
[
768,
24,
1090
]
],
[
[
768,
24,
144
],
[
144,
63,
1090
]
],
[
[
768,
63,
688
],
[
688,
24,
1090
]
],
[
[
768,
64,
222
],
[
222,
... | [
[
[
"Tapentadol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tetryzoline"
]
],
[
[
"Tapentadol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Olodaterol"
],
[
... | Tapentadol may cause a moderate interaction that could exacerbate diseases when taken with Tetryzoline
Tapentadol may cause a moderate interaction that could exacerbate diseases when taken with Olodaterol and Olodaterol may cause a moderate interaction that could exacerbate diseases when taken with Tetryzoline
Tapentad... |
DB00586 | DB01259 | 1,512 | 392 | [
"DDInter537",
"DDInter1024"
] | Diclofenac | Lapatinib | Diclofenac is a phenylacetic acid derivative and non-steroidal anti-inflammatory drug (NSAID).[label] NSAIDs inhibit cyclooxygenase (COX)-1 and-2 which are the enzyme responsible for producing prostaglandins (PGs). PGs contribute to inflammation and pain signalling. Diclofenac, like other NSAIDs, is often used as first... | Lapatinib is an anti-cancer drug developed by GlaxoSmithKline (GSK) as a treatment for solid tumours such as breast and lung cancer. It was approved by the FDA on March 13, 2007, for use in patients with advanced metastatic breast cancer in conjunction with the chemotherapy drug capecitabine. Lapatinib is a human epide... | Moderate | 1 | [
[
[
1512,
24,
392
]
],
[
[
1512,
6,
4973
],
[
4973,
45,
392
]
],
[
[
1512,
21,
28674
],
[
28674,
60,
392
]
],
[
[
1512,
23,
479
],
[
479,
... | [
[
[
"Diclofenac",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lapatinib"
]
],
[
[
"Diclofenac",
"{u} (Compound) binds {v} (Gene)",
"ABCB1"
],
[
"ABCB1",
"{u} (Gene) is bound by {v} (Compound)",
... | Diclofenac (Compound) binds ABCB1 (Gene) and ABCB1 (Gene) is bound by Lapatinib (Compound)
Diclofenac (Compound) causes Nail disorder (Side Effect) and Nail disorder (Side Effect) is caused by Lapatinib (Compound)
Diclofenac may cause a minor interaction that can limit clinical effects when taken with Donepezil and Don... |
DB00580 | DB08816 | 311 | 578 | [
"DDInter1910",
"DDInter1802"
] | Valdecoxib | Ticagrelor | Valdecoxib was removed from the Canadian, U.S., and E.U. markets in 2005 due to concerns about a possible increased risk of heart attack and stroke. | Ticagrelor, or AZD6140, was first described in the literature in 2003.[A204170,A2903] Ticagrelor is an ADP derivative developed for its P2Y<sub>12</sub> receptor antagonism. Unlike [clopidogrel], ticagrelor is not a prodrug. It is marketed by Astra Zeneca as Brilinta in the US and Brilique or Possia in the EU,. Ticagre... | Moderate | 1 | [
[
[
311,
24,
578
]
],
[
[
311,
63,
1578
],
[
1578,
24,
578
]
],
[
[
311,
24,
723
],
[
723,
24,
578
]
],
[
[
311,
24,
1476
],
[
1476,
... | [
[
[
"Valdecoxib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ticagrelor"
]
],
[
[
"Valdecoxib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lepirudin"
],
[
... | Valdecoxib may cause a moderate interaction that could exacerbate diseases when taken with Lepirudin and Lepirudin may cause a moderate interaction that could exacerbate diseases when taken with Ticagrelor
Valdecoxib may cause a moderate interaction that could exacerbate diseases when taken with Aprepitant and Aprepita... |
DB08875 | DB11952 | 1,618 | 800 | [
"DDInter262",
"DDInter612"
] | Cabozantinib | Duvelisib | Cabozantinib was first approved in 2012 and is a non-specific tyrosine kinase inhibitor. It was initially approved in the US under the brand name Cometriq, which is indicated for the treatment of metastatic medullary thyroid cancer. In 2016, a capsule formulation (Cabometyx) was approved for the treatment of advanced r... | Duvelisib, also known as IPI-145 and INK-1197, is a small-molecule inhibitor of phosphoinositide-3 kinases that was designed initially to prove that simultaneous inhibition of the isoforms delta and gamma can produce a broad adaptative and innate immune cell inhibitory activity. All the work around duvelisib showed tha... | Moderate | 1 | [
[
[
1618,
24,
800
]
],
[
[
1618,
63,
222
],
[
222,
23,
800
]
],
[
[
1618,
24,
1476
],
[
1476,
63,
800
]
],
[
[
1618,
63,
896
],
[
896,
... | [
[
[
"Cabozantinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Duvelisib"
]
],
[
[
"Cabozantinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sibutramine"
],
... | Cabozantinib may cause a moderate interaction that could exacerbate diseases when taken with Sibutramine and Sibutramine may cause a minor interaction that can limit clinical effects when taken with Duvelisib
Cabozantinib may cause a moderate interaction that could exacerbate diseases when taken with Brigatinib and Bri... |
DB04948 | DB08907 | 1,084 | 1,344 | [
"DDInter1083",
"DDInter280"
] | Lofexidine | Canagliflozin | Lofexidine is a non-opioid centrally acting alpha2-adrenergic receptor agonist that was first approved for the treatment of opioid withdrawal in the United Kingdom in 1992. It was first studied for use as an antihypertensive in 1980, but its researched was stopped as it was found less effective for the treatment of hyp... | Canagliflozin, also known as _Invokana_, is a sodium-glucose cotransporter 2 (SGLT2) inhibitor used in the management of type 2 diabetes mellitus along with lifestyle changes including diet and exercise [FDA label]. It was initially approved by the FDA in 2013 for the management of diabetes and later approved in 2018 f... | Moderate | 1 | [
[
[
1084,
24,
1344
]
],
[
[
1084,
24,
549
],
[
549,
1,
1344
]
],
[
[
1084,
63,
1148
],
[
1148,
24,
1344
]
],
[
[
1084,
40,
1020
],
[
1020,... | [
[
[
"Lofexidine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Canagliflozin"
]
],
[
[
"Lofexidine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dapagliflozin"
],
... | Lofexidine may cause a moderate interaction that could exacerbate diseases when taken with Dapagliflozin and Dapagliflozin (Compound) resembles Canagliflozin (Compound)
Lofexidine may cause a moderate interaction that could exacerbate diseases when taken with Isoprenaline and Isoprenaline may cause a moderate interacti... |
DB00549 | DB11575 | 522 | 1,676 | [
"DDInter1955",
"DDInter841"
] | Zafirlukast | Grazoprevir | Zafirlukast is an oral leukotriene receptor antagonist (LTRA) for the maintenance treatment of asthma, often used in conjunction with an inhaled steroid and/or long-acting bronchodilator. It is available as a tablet and is usually dosed twice daily. Another leukotriene receptor antagonist is montelukast (Singulair), wh... | Grazoprevir is a direct acting antiviral medication used as part of combination therapy to treat chronic Hepatitis C, an infectious liver disease caused by infection with Hepatitis C Virus (HCV). HCV is a single-stranded RNA virus that is categorized into nine distinct genotypes, with genotype 1 being the most common i... | Moderate | 1 | [
[
[
522,
24,
1676
]
],
[
[
522,
24,
723
],
[
723,
24,
1676
]
],
[
[
522,
63,
597
],
[
597,
24,
1676
]
],
[
[
522,
24,
351
],
[
351,
... | [
[
[
"Zafirlukast",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Grazoprevir"
]
],
[
[
"Zafirlukast",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Aprepitant"
],
[... | Zafirlukast may cause a moderate interaction that could exacerbate diseases when taken with Aprepitant and Aprepitant may cause a moderate interaction that could exacerbate diseases when taken with Grazoprevir
Zafirlukast may cause a moderate interaction that could exacerbate diseases when taken with Chloramphenicol an... |
DB01211 | DB01611 | 609 | 1,487 | [
"DDInter393",
"DDInter893"
] | Clarithromycin | Hydroxychloroquine | Clarithromycin, a semisynthetic macrolide antibiotic derived from erythromycin, inhibits bacterial protein synthesis by binding to the bacterial 50S ribosomal subunit. Binding inhibits peptidyl transferase activity and interferes with amino acid translocation during the translation and protein assembly process. Clarith... | Hydroxychloroquine is a racemic mixture consisting of an R and S enantiomer. Hydroxychloroquine is an aminoquinoline like [chloroquine]. It is a commonly prescribed medication in the treatment of uncomplicated malaria, rheumatoid arthritis, chronic discoid lupus erythematosus, and systemic lupus erythematosus. Hydroxyc... | Major | 2 | [
[
[
609,
25,
1487
]
],
[
[
609,
63,
1520
],
[
1520,
25,
1487
]
],
[
[
609,
21,
28658
],
[
28658,
60,
1487
]
],
[
[
609,
62,
1247
],
[
1247... | [
[
[
"Clarithromycin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Hydroxychloroquine"
]
],
[
[
"Clarithromycin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Primaquine"
],
[
... | Clarithromycin may cause a moderate interaction that could exacerbate diseases when taken with Primaquine and Primaquine may lead to a major life threatening interaction when taken with Hydroxychloroquine
Clarithromycin (Compound) causes Vomiting (Side Effect) and Vomiting (Side Effect) is caused by Hydroxychloroquine ... |
DB00059 | DB00976 | 1,560 | 1,056 | [
"DDInter1404",
"DDInter1758"
] | Pegaspargase | Telithromycin | Pegaspargase is a conjugate of monomethoxypolyethylene glycol (mPEG) and L-asparaginase (L-asparagine amidohydrolase), an asparagine-specific enzyme that converts L-asparagine into aspartic acid and ammonia. Asparagine is an amino acid that is vital for cell survival. In humans, most normal tissues can produce asparagi... | Telithromycin, a semi-synthetic erythromycin derivative, belongs to a new chemical class of antibiotics called ketolides. Ketolides have been recently added to the macrolide-lincosamide-streptogramin class of antibiotics. Similar to the macrolide antibiotics, telithromycin prevents bacterial growth by interfering with ... | Moderate | 1 | [
[
[
1560,
24,
1056
]
],
[
[
1560,
24,
1570
],
[
1570,
40,
1056
]
],
[
[
1560,
24,
1220
],
[
1220,
63,
1056
]
],
[
[
1560,
24,
79
],
[
79,
... | [
[
[
"Pegaspargase",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Telithromycin"
]
],
[
[
"Pegaspargase",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Azithromycin"
],... | Pegaspargase may cause a moderate interaction that could exacerbate diseases when taken with Azithromycin and Azithromycin (Compound) resembles Telithromycin (Compound)
Pegaspargase may cause a moderate interaction that could exacerbate diseases when taken with Dexamethasone and Dexamethasone may cause a moderate inter... |
DB00674 | DB06595 | 1,516 | 1,491 | [
"DDInter802",
"DDInter1214"
] | Galantamine | Midostaurin | Galantamine is a tertiary alkaloid and reversible, competitive inhibitor of the acetylcholinesterase (AChE) enzyme, which is a widely studied therapeutic target used in the treatment of Alzheimer's disease. First characterized in the early 1950s, galantamine is a tertiary alkaloid that was extracted from botanical sour... | Midostaurin (as Rydapt) is a multitarget kinase inhibitor for the treatment for adult patients with newly diagnosed acute myeloid leukemia (AML) who have a specific genetic mutation called FLT3. It was initially characterized as a potential broad-spectrum antineoplastic agent, with activity toward diverse solid and hem... | Moderate | 1 | [
[
[
1516,
24,
1491
]
],
[
[
1516,
24,
112
],
[
112,
23,
1491
]
],
[
[
1516,
24,
888
],
[
888,
24,
1491
]
],
[
[
1516,
24,
1017
],
[
1017,
... | [
[
[
"Galantamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Midostaurin"
]
],
[
[
"Galantamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Metronidazole"
],
... | Galantamine may cause a moderate interaction that could exacerbate diseases when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Midostaurin
Galantamine may cause a moderate interaction that could exacerbate diseases when taken with Tamoxifen and ... |
DB00398 | DB06817 | 79 | 809 | [
"DDInter1702",
"DDInter1563"
] | Sorafenib | Raltegravir | Sorafenib is a bi-aryl urea and an oral multikinase inhibitor. It targets cell surface tyrosine kinase receptors and downstream intracellular kinases that are implicated in tumour cell proliferation and tumour angiogenesis. First approved by the FDA and European Commission in 2007 for the treatment of hepatocellular ca... | Raltegravir is an antiretroviral drug produced by Merck & Co., used to treat HIV infection. It received approval by the U.S. Food and Drug Administration (FDA) on 12 October 2007, the first of a new class of HIV drugs, the integrase inhibitors, to receive such approval. | Minor | 0 | [
[
[
79,
23,
809
]
],
[
[
79,
6,
15705
],
[
15705,
45,
809
]
],
[
[
79,
7,
7806
],
[
7806,
57,
809
]
],
[
[
79,
21,
29122
],
[
29122,
... | [
[
[
"Sorafenib",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Raltegravir"
]
],
[
[
"Sorafenib",
"{u} (Compound) binds {v} (Gene)",
"UGT1A1"
],
[
"UGT1A1",
"{u} (Gene) is bound by {v} (Compound)",
... | Sorafenib (Compound) binds UGT1A1 (Gene) and UGT1A1 (Gene) is bound by Raltegravir (Compound)
Sorafenib (Compound) upregulates INPP1 (Gene) and INPP1 (Gene) is downregulated by Raltegravir (Compound)
Sorafenib (Compound) causes Mediastinal disorder (Side Effect) and Mediastinal disorder (Side Effect) is caused by Ralte... |
DB00015 | DB01225 | 582 | 500 | [
"DDInter1585",
"DDInter645"
] | Reteplase | Enoxaparin | Human tissue plasminogen activator, purified, glycosylated, 355 residues purified from CHO cells. Retavase is considered a "third-generation" thrombolytic agent, genetically engineered to retain and delete certain portions of human tPA. Retavase is a deletion mutein of human tPA formed by deleting various amino acids p... | Enoxaparin is a common low-molecular-weight heparin (LMWH) used in the prevention and management of various thromboembolic disorders. Initially approved by the FDA in 1993, it is administered by a subcutaneous or intravenous injection and marketed by several pharmaceutical companies. Enoxaparin markedly reduces the inc... | Major | 2 | [
[
[
582,
25,
500
]
],
[
[
582,
23,
1631
],
[
1631,
62,
500
]
],
[
[
582,
24,
1004
],
[
1004,
63,
500
]
],
[
[
582,
24,
311
],
[
311,
... | [
[
[
"Reteplase",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Enoxaparin"
]
],
[
[
"Reteplase",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Turmeric"
],
[
"Turmeric",
... | Reteplase may cause a minor interaction that can limit clinical effects when taken with Turmeric and Turmeric may cause a minor interaction that can limit clinical effects when taken with Enoxaparin
Reteplase may cause a moderate interaction that could exacerbate diseases when taken with Phenyl salicylate and Phenyl sa... |
DB06292 | DB08815 | 549 | 154 | [
"DDInter474",
"DDInter1104"
] | Dapagliflozin | Lurasidone | Dapagliflozin is a sodium-glucose cotransporter 2 (SGLT2) inhibitor, and it was the first SLGT2 inhibitor to be approved. indicated for managing diabetes mellitus type 2. When combined with diet and exercise in adults, dapagliflozin helps to improve glycemic control by inhibiting glucose reabsorption in the proximal tu... | Lurasidone is an atypical antipsychotic developed by Dainippon Sumitomo Pharma. It was approved by the U.S. Food and Drug Administration (FDA) for treatment of schizophrenia on October 29, 2010 and is currently pending approval for the treatment of bipolar disorder in the United States. | Moderate | 1 | [
[
[
549,
24,
154
]
],
[
[
549,
6,
8374
],
[
8374,
45,
154
]
],
[
[
549,
21,
28921
],
[
28921,
60,
154
]
],
[
[
549,
24,
1033
],
[
1033,
... | [
[
[
"Dapagliflozin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lurasidone"
]
],
[
[
"Dapagliflozin",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compo... | Dapagliflozin (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Lurasidone (Compound)
Dapagliflozin (Compound) causes Dizziness (Side Effect) and Dizziness (Side Effect) is caused by Lurasidone (Compound)
Dapagliflozin may cause a moderate interaction that could exacerbate diseases when taken with Alpelisib ... |
DB00754 | DB09122 | 157 | 1,613 | [
"DDInter696",
"DDInter1409"
] | Ethotoin | Peginterferon beta-1a | Ethotoin is a hydantoin derivative and anticonvulsant. Ethotoin exerts an antiepileptic effect without causing general central nervous system depression. The mechanism of action is probably very similar to that of phenytoin. The latter drug appears to stabilize rather than to raise the normal seizure threshold, and to ... | Multiple Sclerosis (MS) is a chronic and inflammatory autoimmune disease of the central nervous system, disrupting communication between the brain and other parts of the body. Most patients diagnosed with this illness experience their initial disease symptoms between the age of 20 to 40, often the most productive years... | Moderate | 1 | [
[
[
157,
24,
1613
]
],
[
[
157,
64,
600
],
[
600,
24,
1613
]
],
[
[
157,
63,
267
],
[
267,
24,
1613
]
],
[
[
157,
24,
609
],
[
609,
... | [
[
[
"Ethotoin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Peginterferon beta-1a"
]
],
[
[
"Ethotoin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Fluconazole"
],
[
"Fl... | Ethotoin may lead to a major life threatening interaction when taken with Fluconazole and Fluconazole may cause a moderate interaction that could exacerbate diseases when taken with Peginterferon beta-1a
Ethotoin may cause a moderate interaction that could exacerbate diseases when taken with Naltrexone and Naltrexone m... |
DB00495 | DB01234 | 139 | 1,220 | [
"DDInter1961",
"DDInter513"
] | Zidovudine | Dexamethasone | A dideoxynucleoside compound in which the 3'-hydroxy group on the sugar moiety has been replaced by an azido group. This modification prevents the formation of phosphodiester linkages which are needed for the completion of nucleic acid chains. The compound is a potent inhibitor of HIV replication, acting as a chain... | Dexamethasone, or MK-125, is a corticosteroid fluorinated at position 9 used to treat endocrine, rheumatic, collagen, dermatologic, allergic, ophthalmic, gastrointestinal, respiratory, hematologic, neoplastic, edematous, and other conditions. Developed in 1957, it is structurally similar to other corticosteroids like [... | Moderate | 1 | [
[
[
139,
24,
1220
]
],
[
[
139,
24,
870
],
[
870,
1,
1220
]
],
[
[
139,
24,
175
],
[
175,
40,
1220
]
],
[
[
139,
63,
251
],
[
251,
1... | [
[
[
"Zidovudine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dexamethasone"
]
],
[
[
"Zidovudine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fludrocortisone"
],
... | Zidovudine may cause a moderate interaction that could exacerbate diseases when taken with Fludrocortisone and Fludrocortisone (Compound) resembles Dexamethasone (Compound)
Zidovudine may cause a moderate interaction that could exacerbate diseases when taken with Triamcinolone and Triamcinolone (Compound) resembles Dex... |
DB00986 | DB06016 | 1,192 | 1,508 | [
"DDInter834",
"DDInter300"
] | Glycopyrronium | Cariprazine | Glycopyrronium, also known as NVA237 or glycopyrrolate, is a racemic mixture of two enantiomers. They are both quaternary ammonium compounds and long acting muscarinic antagonists. It is one of the most commonly prescribed anticholinergic medications.[A233535,A233540] Early research into glycopyrronium use was for its ... | Cariprazine is an atypical antipsychotic agent and a piperazine derivative that was first developed in Hungary. It works as a partial agonist at central dopamine D2, dopamine D3, and serotonin 5-HT<sub>1A</sub> receptors and as an antagonist at serotonin 5-HT<sub>2A</sub> receptors. Cariprazine has been investigated in... | Moderate | 1 | [
[
[
1192,
24,
1508
]
],
[
[
1192,
63,
1507
],
[
1507,
24,
1508
]
],
[
[
1192,
24,
272
],
[
272,
24,
1508
]
],
[
[
1192,
24,
849
],
[
849,
... | [
[
[
"Glycopyrronium",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cariprazine"
]
],
[
[
"Glycopyrronium",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dicyclomine"
]... | Glycopyrronium may cause a moderate interaction that could exacerbate diseases when taken with Dicyclomine and Dicyclomine may cause a moderate interaction that could exacerbate diseases when taken with Cariprazine
Glycopyrronium may cause a moderate interaction that could exacerbate diseases when taken with Chlorpheni... |
DB01088 | DB12500 | 714 | 283 | [
"DDInter908",
"DDInter714"
] | Iloprost | Fedratinib | Iloprost is a mimetic of prostacyclin (PGI2; epoprostenol). Iloprost consists of a mixture of the 4R and 4S diastereoisomers at a ratio of approximately 53:47. It is a potent vasodilator with reported anti-thrombotic properties. | Fedratinib, also known as SAR302503 and TG101348, is a tyrosine kinase inhibitor used to treat intermediate-2 and high risk primary and secondary myelofibrosis.[A183176,L8090] It is an anilinopyrimidine derivative. Fedratinib was granted FDA approval on August 16, 2019. | Moderate | 1 | [
[
[
714,
24,
283
]
],
[
[
714,
63,
122
],
[
122,
23,
283
]
],
[
[
714,
24,
336
],
[
336,
24,
283
]
],
[
[
714,
63,
529
],
[
529,
24,... | [
[
[
"Iloprost",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fedratinib"
]
],
[
[
"Iloprost",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Verapamil"
],
[
"... | Iloprost may cause a moderate interaction that could exacerbate diseases when taken with Verapamil and Verapamil may cause a minor interaction that can limit clinical effects when taken with Fedratinib
Iloprost may cause a moderate interaction that could exacerbate diseases when taken with Nifedipine and Nifedipine may... |
DB00529 | DB09080 | 789 | 144 | [
"DDInter779",
"DDInter1331"
] | Foscarnet | Olodaterol | An antiviral agent used in the treatment of cytomegalovirus retinitis. Foscarnet also shows activity against human herpes viruses and HIV. | Olodaterol is a novel, long-acting beta2-adrenergic agonist (LABA) that exerts its pharmacological effect by binding and activating beta2-adrenergic receptors located primarily in the lungs. Beta2-adrenergic receptors are membrane-bound receptors that are normally activated by endogenous epinephrine whose signalling, v... | Moderate | 1 | [
[
[
789,
24,
144
]
],
[
[
789,
25,
1011
],
[
1011,
24,
144
]
],
[
[
789,
24,
543
],
[
543,
24,
144
]
],
[
[
789,
63,
322
],
[
322,
2... | [
[
[
"Foscarnet",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Olodaterol"
]
],
[
[
"Foscarnet",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Fingolimod"
],
[
"Fingolimod",... | Foscarnet may lead to a major life threatening interaction when taken with Fingolimod and Fingolimod may cause a moderate interaction that could exacerbate diseases when taken with Olodaterol
Foscarnet may cause a moderate interaction that could exacerbate diseases when taken with Loperamide and Loperamide may cause a ... |
DB00005 | DB00242 | 1,057 | 1,064 | [
"DDInter687",
"DDInter392"
] | Etanercept | Cladribine | Dimeric fusion protein consisting of the extracellular ligand-binding portion of the human 75 kilodalton (p75) tumor necrosis factor receptor (TNFR) linked to the Fc portion of human IgG1.[L14862,A216522] The Fc component of etanercept contains the CH2 domain, the CH3 domain and hinge region, but not the CH1 domain of ... | An antineoplastic agent used in the treatment of lymphoproliferative diseases including hairy-cell leukemia. | Major | 2 | [
[
[
1057,
25,
1064
]
],
[
[
1057,
25,
1426
],
[
1426,
64,
1064
]
],
[
[
1057,
24,
1525
],
[
1525,
63,
1064
]
],
[
[
1057,
25,
869
],
[
869... | [
[
[
"Etanercept",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Cladribine"
]
],
[
[
"Etanercept",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Azacitidine"
],
[
"Azacitidine",
"{u}... | Etanercept may lead to a major life threatening interaction when taken with Azacitidine and Azacitidine may lead to a major life threatening interaction when taken with Cladribine
Etanercept may cause a moderate interaction that could exacerbate diseases when taken with Dienogest and Dienogest may cause a moderate inte... |
DB00380 | DB14409 | 145 | 1,129 | [
"DDInter522",
"DDInter867"
] | Dexrazoxane | Human adenovirus e serotype 4 strain cl-68578 antigen | An antimitotic agent with immunosuppressive properties. Dexrazoxane, the (+)-enantiomorph of razoxane, provides cardioprotection against anthracycline toxicity. It appears to inhibit formation of a toxic iron-anthracycline complex. [PubChem] The Food and Drug Administration has designated dexrazoxane as an orphan drug ... | Human adenovirus e serotype 4 strain cl-68578 antigen is a vaccine. | Moderate | 1 | [
[
[
145,
24,
1129
]
],
[
[
145,
24,
713
],
[
713,
24,
1129
]
],
[
[
145,
6,
3930
],
[
3930,
45,
51
],
[
51,
24,
1129
]
],
[
[
145,
2... | [
[
[
"Dexrazoxane",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Human adenovirus e serotype 4 strain cl-68578 antigen"
]
],
[
[
"Dexrazoxane",
"{u} may cause a moderate interaction that could exacerbate diseases when taken ... | Dexrazoxane may cause a moderate interaction that could exacerbate diseases when taken with Dimethyl fumarate and Dimethyl fumarate may cause a moderate interaction that could exacerbate diseases when taken with Human adenovirus e serotype 4 strain cl-68578 antigen
Dexrazoxane (Compound) binds TOP2B (Gene) and TOP2B (G... |
DB00294 | DB11901 | 1,336 | 913 | [
"DDInter701",
"DDInter107"
] | Etonogestrel | Apalutamide | Etonogestrel molecule is a 3-ketodesogestrel or 19-nortestosterone which is a synthetic biologically active metabolite of progestin desogestrel. The first product including etonogestrel was developed by the Merck subsidiary Organon and FDA approved in 2001. | Apalutamide is a potent androgen receptor (AR) antagonist that selectively binds to the ligand-binding domain of AR and blocks AR nuclear translocation or binding to androgen response elements . It has been used in trials studying the treatment of Prostate Cancer, Hepatic Impairment, Prostatic Neoplasms, Castration-Res... | Moderate | 1 | [
[
[
1336,
24,
913
]
],
[
[
1336,
63,
600
],
[
600,
24,
913
]
],
[
[
1336,
40,
1197
],
[
1197,
24,
913
]
],
[
[
1336,
24,
609
],
[
609,
... | [
[
[
"Etonogestrel",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Apalutamide"
]
],
[
[
"Etonogestrel",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fluconazole"
],
... | Etonogestrel may cause a moderate interaction that could exacerbate diseases when taken with Fluconazole and Fluconazole may cause a moderate interaction that could exacerbate diseases when taken with Apalutamide
Etonogestrel (Compound) resembles Norethisterone (Compound) and Norethisterone may cause a moderate interac... |
DB00104 | DB00696 | 966 | 826 | [
"DDInter1323",
"DDInter665"
] | Octreotide | Ergotamine | Acromegaly is a disorder caused by excess growth hormone (GH), increasing the growth of body tissues and causing metabolic dysfunction. In most cases, it results from an anterior pituitary growth hormone-releasing tumor. Typically, the feet, hands, and face grow abnormally large; organomegaly and insulin resistance may... | A vasoconstrictor found in ergot of Central Europe. It is an alpha-1 selective adrenergic agonist and is commonly used in the treatment of migraine disorders. | Moderate | 1 | [
[
[
966,
24,
826
]
],
[
[
966,
24,
469
],
[
469,
40,
826
]
],
[
[
966,
24,
588
],
[
588,
1,
826
]
],
[
[
966,
21,
28996
],
[
28996,
... | [
[
[
"Octreotide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ergotamine"
]
],
[
[
"Octreotide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bromocriptine"
],
[... | Octreotide may cause a moderate interaction that could exacerbate diseases when taken with Bromocriptine and Bromocriptine (Compound) resembles Ergotamine (Compound)
Octreotide may cause a moderate interaction that could exacerbate diseases when taken with Methylergometrine and Methylergometrine (Compound) resembles Er... |
DB00312 | DB00835 | 1,023 | 100 | [
"DDInter1423",
"DDInter245"
] | Pentobarbital | Brompheniramine | A short-acting barbiturate that is effective as a sedative and hypnotic (but not as an anti-anxiety) agent and is usually given orally. It is prescribed more frequently for sleep induction than for sedation but, like similar agents, may lose its effectiveness by the second week of continued administration. (From AMA Dr... | Histamine H1 antagonist used in treatment of allergies, rhinitis, and urticaria. | Moderate | 1 | [
[
[
1023,
24,
100
]
],
[
[
1023,
24,
832
],
[
832,
24,
100
]
],
[
[
1023,
24,
649
],
[
649,
63,
100
]
],
[
[
1023,
6,
8374
],
[
8374,
... | [
[
[
"Pentobarbital",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Brompheniramine"
]
],
[
[
"Pentobarbital",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tripelennamine"
... | Pentobarbital may cause a moderate interaction that could exacerbate diseases when taken with Tripelennamine and Tripelennamine may cause a moderate interaction that could exacerbate diseases when taken with Brompheniramine
Pentobarbital may cause a moderate interaction that could exacerbate diseases when taken with Cl... |
DB01157 | DB14783 | 304 | 287 | [
"DDInter1875",
"DDInter574"
] | Trimetrexate | Diroximel fumarate | A nonclassical folic acid inhibitor through its inhibition of the enzyme dihydrofolate reductase. It is being tested for efficacy as an antineoplastic agent and as an antiparasitic agent against pneumocystis pneumonia in AIDS patients. Myelosuppression is its dose-limiting toxic effect. | Multiple Sclerosis (MS) is a chronic, debilitating neurological disease that can lead to profound cognitive and physical symptoms, severely affecting quality of life. It is the main cause of neurological disability not caused by trauma in the young adult population of both North America and Europe. Relapsing-remitting ... | Moderate | 1 | [
[
[
304,
24,
287
]
],
[
[
304,
63,
1560
],
[
1560,
24,
287
]
],
[
[
304,
24,
384
],
[
384,
24,
287
]
],
[
[
304,
25,
1510
],
[
1510,
... | [
[
[
"Trimetrexate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Diroximel fumarate"
]
],
[
[
"Trimetrexate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pegaspargase"
... | Trimetrexate may cause a moderate interaction that could exacerbate diseases when taken with Pegaspargase and Pegaspargase may cause a moderate interaction that could exacerbate diseases when taken with Diroximel fumarate
Trimetrexate may cause a moderate interaction that could exacerbate diseases when taken with Idela... |
DB00295 | DB01197 | 475 | 1,603 | [
"DDInter1244",
"DDInter292"
] | Morphine | Captopril | Morphine, the main alkaloid of opium, was first obtained from poppy seeds in 1805. It is a potent analgesic, though its use is limited due to tolerance, withdrawal, and the risk of abuse. Morphine is still routinely used today, though there are a number of semi-synthetic opioids of varying strength such as [codeine], [... | Captopril is a potent, competitive inhibitor of angiotensin-converting enzyme (ACE), the enzyme responsible for the conversion of angiotensin I (ATI) to angiotensin II (ATII). ATII regulates blood pressure and is a key component of the renin-angiotensin-aldosterone system (RAAS). Captopril may be used in the treatment ... | Moderate | 1 | [
[
[
475,
24,
1603
]
],
[
[
475,
24,
610
],
[
610,
1,
1603
]
],
[
[
475,
10,
11576
],
[
11576,
44,
1603
]
],
[
[
475,
6,
12523
],
[
12523,
... | [
[
[
"Morphine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Captopril"
]
],
[
[
"Morphine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Enalapril"
],
[
"E... | Morphine may cause a moderate interaction that could exacerbate diseases when taken with Enalapril and Enalapril (Compound) resembles Captopril (Compound)
Morphine (Compound) palliates coronary artery disease (Disease) and coronary artery disease (Disease) is treated by Captopril (Compound)
Morphine (Compound) binds CY... |
DB00331 | DB01059 | 1,645 | 956 | [
"DDInter1164",
"DDInter1313"
] | Metformin | Norfloxacin | Metformin is a biguanide antihyperglycemic agent and first-line pharmacotherapy used in the management of type II diabetes.[L12207,A176173] Metformin is considered an antihyperglycemic drug because it lowers blood glucose concentrations in type II diabetes without causing hypoglycemia. It is commonly described as an "i... | A synthetic fluoroquinolone (fluoroquinolones) with broad-spectrum antibacterial activity against most gram-negative and gram-positive bacteria. Norfloxacin inhibits bacterial DNA gyrase. | Moderate | 1 | [
[
[
1645,
24,
956
]
],
[
[
1645,
24,
872
],
[
872,
40,
956
]
],
[
[
1645,
63,
1176
],
[
1176,
1,
956
]
],
[
[
1645,
24,
1539
],
[
1539,
... | [
[
[
"Metformin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Norfloxacin"
]
],
[
[
"Metformin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Gemifloxacin"
],
[
... | Metformin may cause a moderate interaction that could exacerbate diseases when taken with Gemifloxacin and Gemifloxacin (Compound) resembles Norfloxacin (Compound)
Metformin may cause a moderate interaction that could exacerbate diseases when taken with Moxifloxacin and Moxifloxacin (Compound) resembles Norfloxacin (Co... |
DB00759 | DB09054 | 1,620 | 384 | [
"DDInter1783",
"DDInter905"
] | Tetracycline | Idelalisib | Tetracycline is a broad spectrum polyketide antibiotic produced by the Streptomyces genus of Actinobacteria. It exerts a bacteriostatic effect on bacteria by binding reversible to the bacterial 30S ribosomal subunit and blocking incoming aminoacyl tRNA from binding to the ribosome acceptor site. It also binds to some e... | Idelalisib is a phosphoinositide 3-kinase inhibitor indicated in the treatment of chronic lymphocytic leukemia (CLL), relapsed follicular B-cell non-Hodgkin lymphoma (FL), and relapsed small lymphocytic lymphoma (SLL). For the treatment of relapsed CLL, it is currently indicated as a second-line agent in combination wi... | Moderate | 1 | [
[
[
1620,
24,
384
]
],
[
[
1620,
63,
305
],
[
305,
24,
384
]
],
[
[
1620,
24,
242
],
[
242,
63,
384
]
],
[
[
1620,
24,
954
],
[
954,
... | [
[
[
"Tetracycline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Idelalisib"
]
],
[
[
"Tetracycline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Asparaginase Escherichi... | Tetracycline may cause a moderate interaction that could exacerbate diseases when taken with Asparaginase Escherichia coli and Asparaginase Escherichia coli may cause a moderate interaction that could exacerbate diseases when taken with Idelalisib
Tetracycline may cause a moderate interaction that could exacerbate dise... |
DB00334 | DB00427 | 867 | 1,233 | [
"DDInter1326",
"DDInter1879"
] | Olanzapine | Triprolidine | Olanzapine is a thienobenzodiazepine classified as an atypical or second-generation antipsychotic agent. The second-generation antipsychotics were introduced in the 90s and quickly gained traction due to their impressive efficacy, reduced risk for extrapyramidal side effects and reduced susceptibility to drug-drug inte... | First generation histamine H1 antagonist used in allergic rhinitis; asthma; and urticaria. It is a component of cough and cold medicines. It may cause drowsiness. | Moderate | 1 | [
[
[
867,
24,
1233
]
],
[
[
867,
6,
12523
],
[
12523,
45,
1233
]
],
[
[
867,
24,
262
],
[
262,
63,
1233
]
],
[
[
867,
1,
695
],
[
695,
... | [
[
[
"Olanzapine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Triprolidine"
]
],
[
[
"Olanzapine",
"{u} (Compound) binds {v} (Gene)",
"CYP2D6"
],
[
"CYP2D6",
"{u} (Gene) is bound by {v} (Compound)... | Olanzapine (Compound) binds CYP2D6 (Gene) and CYP2D6 (Gene) is bound by Triprolidine (Compound)
Olanzapine may cause a moderate interaction that could exacerbate diseases when taken with Clidinium and Clidinium may cause a moderate interaction that could exacerbate diseases when taken with Triprolidine
Olanzapine (Comp... |
DB01276 | DB09564 | 123 | 1,296 | [
"DDInter706",
"DDInter930"
] | Exenatide | Insulin degludec | Exenatide is a glucagon-like peptide-1 (GLP-1) analog. It activates the GLP-1 receptor and increases insulin secretion, decreases glucagon secretion, and slows gastric emptying to improve glycemic control. Exenatide was given FDA approval on April 28, 2005. It is available as immediate- and extended-release formulation... | Insulin degludec is an ultra-long-acting form of insulin used for the treatment of hyperglycemia caused by Type 1 and Type 2 Diabetes.[A18561,A18562,A18563,A18564,A174934] Insulin is typically prescribed for the management of diabetes mellitus to mimic the activity of endogenously produced human insulin, a peptide horm... | Moderate | 1 | [
[
[
123,
24,
1296
]
],
[
[
123,
62,
1103
],
[
1103,
23,
1296
]
],
[
[
123,
63,
1411
],
[
1411,
24,
1296
]
],
[
[
123,
24,
659
],
[
659,
... | [
[
[
"Exenatide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Insulin degludec"
]
],
[
[
"Exenatide",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Amcinonide"
],
[
... | Exenatide may cause a minor interaction that can limit clinical effects when taken with Amcinonide and Amcinonide may cause a minor interaction that can limit clinical effects when taken with Insulin degludec
Exenatide may cause a moderate interaction that could exacerbate diseases when taken with Tolbutamide and Tolbu... |
DB00252 | DB00650 | 362 | 1,147 | [
"DDInter1460",
"DDInter1041"
] | Phenytoin | Leucovorin | Phenytoin is classified as a hydantoin derivative and despite its narrow therapeutic index, it is one of the most commonly used anticonvulsants.[A33595,A188832,A189219] Since it's introduction about 80 years ago, phenytoin has not only been established as an effective anti-epileptic, but has also been investigated for ... | Folinic Acid (also known as 5-formyl tetrahydrofolic acid or leucovorin) is the 5-formyl derivative of tetrahydrofolic acid, a necessary co-factor in the body. Commercially available leucovorin is composed of a 1:1 racemic mixture of the dextrorotary and levorotary isomers, while levoleucovorin contains only the pharma... | Moderate | 1 | [
[
[
362,
24,
1147
]
],
[
[
362,
63,
356
],
[
356,
1,
1147
]
],
[
[
362,
6,
5912
],
[
5912,
45,
1147
]
],
[
[
362,
21,
28929
],
[
28929,
... | [
[
[
"Phenytoin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Leucovorin"
]
],
[
[
"Phenytoin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Folic acid"
],
[
... | Phenytoin may cause a moderate interaction that could exacerbate diseases when taken with Folic acid and Folic acid (Compound) resembles Leucovorin (Compound)
Phenytoin (Compound) binds ABCC2 (Gene) and ABCC2 (Gene) is bound by Leucovorin (Compound)
Phenytoin (Compound) causes Confusional state (Side Effect) and Confus... |
DB00014 | DB00365 | 521 | 839 | [
"DDInter839",
"DDInter842"
] | Goserelin | Grepafloxacin | Goserelin is a synthetic hormone. In men, it stops the production of the hormone testosterone, which may stimulate the growth of cancer cells. In women, goserelin decreases the production of the hormone estradiol (which may stimulate the growth of cancer cells) to levels similar to a postmenopausal state. When the medi... | Grepafloxacin is an oral broad-spectrum quinoline antibacterial agent used to treat bacterial infections. Due to the QTc-prolonging potential, as indicated by the changes in the QT interval on the electrocardiogram, and the risk for cardiovascular adverse events, grepafloxacin was withdrawn in the United States. | Major | 2 | [
[
[
521,
25,
839
]
],
[
[
521,
23,
112
],
[
112,
62,
839
]
],
[
[
521,
24,
1385
],
[
1385,
63,
839
]
],
[
[
521,
24,
1645
],
[
1645,
... | [
[
[
"Goserelin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Grepafloxacin"
]
],
[
[
"Goserelin",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Metronidazole"
],
[
"Metronid... | Goserelin may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Grepafloxacin
Goserelin may cause a moderate interaction that could exacerbate diseases when taken with Semaglutide and Se... |
DB00620 | DB11817 | 175 | 1,259 | [
"DDInter1855",
"DDInter165"
] | Triamcinolone | Baricitinib | Triamcinolone is a corticosteroid used to treat various inflammatory conditions in the body from allergic rhinitis to acute exacerbations of multiple sclerosis. Triamcinolone can be used as a one time adjunct treatment of osteoarthritic knee pain, or first line as a topical treatment of corticosteroid responsive dermat... | Baricitinib is a Janus kinase (JAK) inhibitor. JAKs are tyrosine protein kinases that play an important role in pro-inflammatory signaling pathways. Overactive JAKs have been implicated in autoimmune disorders, such as rheumatoid arthritis. By inhibiting the actions of JAK1 and JAK2, baricitinib attenuates JAK-mediated... | Major | 2 | [
[
[
175,
25,
1259
]
],
[
[
175,
23,
1193
],
[
1193,
23,
1259
]
],
[
[
175,
62,
1461
],
[
1461,
23,
1259
]
],
[
[
175,
24,
1274
],
[
1274,
... | [
[
[
"Triamcinolone",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Baricitinib"
]
],
[
[
"Triamcinolone",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Zinc gluconate"
],
[
"Z... | Triamcinolone may cause a minor interaction that can limit clinical effects when taken with Zinc gluconate and Zinc gluconate may cause a minor interaction that can limit clinical effects when taken with Baricitinib
Triamcinolone may cause a minor interaction that can limit clinical effects when taken with Vitamin E an... |
DB00631 | DB01219 | 372 | 716 | [
"DDInter405",
"DDInter473"
] | Clofarabine | Dantrolene | Clofarabine is a purine nucleoside antimetabolite that is being studied in the treatment of cancer. It is marketed as Clolar in the U.S. and Canada, or Evoltra in Europe, Australia, and New Zealand. Clofarabine is used in paediatrics to treat a type of leukaemia called relapsed or refractory acute lymphoblastic leukaem... | Chemically, dantrolene is a hydantoin derivative, but does not exhibit antiepileptic activity like other hydantoin derivates such as phenytoin. | Moderate | 1 | [
[
[
372,
24,
716
]
],
[
[
372,
21,
28746
],
[
28746,
60,
716
]
],
[
[
372,
24,
267
],
[
267,
24,
716
]
],
[
[
372,
24,
1613
],
[
1613,
... | [
[
[
"Clofarabine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dantrolene"
]
],
[
[
"Clofarabine",
"{u} (Compound) causes {v} (Side Effect)",
"Erythema"
],
[
"Erythema",
"{u} (Side Effect) is caus... | Clofarabine (Compound) causes Erythema (Side Effect) and Erythema (Side Effect) is caused by Dantrolene (Compound)
Clofarabine may cause a moderate interaction that could exacerbate diseases when taken with Naltrexone and Naltrexone may cause a moderate interaction that could exacerbate diseases when taken with Dantrol... |
DB01076 | DB11569 | 700 | 1,093 | [
"DDInter133",
"DDInter1003"
] | Atorvastatin | Ixekizumab | Atorvastatin (Lipitor®), is a lipid-lowering drug included in the statin class of medications. By inhibiting the endogenous production of cholesterol in the liver, statins lower abnormal cholesterol and lipid levels, and ultimately reduce the risk of cardiovascular disease. More specifically, statin medications competi... | Ixekizumab is a humanized immunoglobulin G subclass 4 (IgG4) monoclonal antibody (mAb) against interleukin-17A (IL-17A) and prevents it from interacting with the IL-17A receptor. As IL-17A is a pro-inflammatory cytokine involved in inflammation and immune responses, blocking its effect is beneficial for use in inflamma... | Moderate | 1 | [
[
[
700,
24,
1093
]
],
[
[
700,
63,
134
],
[
134,
24,
1093
]
],
[
[
700,
24,
1683
],
[
1683,
24,
1093
]
],
[
[
700,
62,
303
],
[
303,
... | [
[
[
"Atorvastatin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ixekizumab"
]
],
[
[
"Atorvastatin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Vinorelbine"
],
... | Atorvastatin may cause a moderate interaction that could exacerbate diseases when taken with Vinorelbine and Vinorelbine may cause a moderate interaction that could exacerbate diseases when taken with Ixekizumab
Atorvastatin may cause a moderate interaction that could exacerbate diseases when taken with Ustekinumab and... |
DB00792 | DB00996 | 832 | 1,198 | [
"DDInter1878",
"DDInter791"
] | Tripelennamine | Gabapentin | A histamine H1 antagonist with low sedative action but frequent gastrointestinal irritation. It is used to treat asthma; HAY fever; urticaria; and rhinitis; and also in veterinary applications. Tripelennamine is administered by various routes, including topically. | Gabapentin is a structural analogue of the inhibitory neurotransmitter gamma-aminobutyric acid ([GABA]) that was first approved for use in the United States in 1993. It was originally developed as a novel anti-epileptic for the treatment of certain types of seizures[A186277,A186143] - today it is also widely used to tr... | Moderate | 1 | [
[
[
832,
24,
1198
]
],
[
[
832,
24,
1311
],
[
1311,
63,
1198
]
],
[
[
832,
63,
530
],
[
530,
24,
1198
]
],
[
[
832,
74,
662
],
[
662,
... | [
[
[
"Tripelennamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Gabapentin"
]
],
[
[
"Tripelennamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Metoclopramide"
... | Tripelennamine may cause a moderate interaction that could exacerbate diseases when taken with Metoclopramide and Metoclopramide may cause a moderate interaction that could exacerbate diseases when taken with Gabapentin
Tripelennamine may cause a moderate interaction that could exacerbate diseases when taken with Drona... |
DB10315 | DB12267 | 1,137 | 1,476 | [
"DDInter1127",
"DDInter233"
] | Measles virus vaccine live attenuated | Brigatinib | Measles virus vaccine live attenuated is a live virus vaccine for simultaneous vaccination against measles, which is a common childhood disease. The vaccine is prepared from the attenuated line of measles virus, derived from Enders' attenuated Edmonston strain and propagated in chick embryo cell culture. | Brigatinib, originally named AP26113, is a reversible dual inhibitor of anaplastic lymphoma kinase (ALK) and epidermal growth factor receptor (EGFR). It presents selectivity against the mutant forms of EGFR compared to the wild-type. It also exhibits selectivity against 9 different Crizotinib-resistant mutants of the E... | Major | 2 | [
[
[
1137,
25,
1476
]
],
[
[
1137,
64,
168
],
[
168,
23,
1476
]
],
[
[
1137,
64,
629
],
[
629,
24,
1476
]
],
[
[
1137,
25,
1456
],
[
1456,
... | [
[
[
"Measles virus vaccine live attenuated",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Brigatinib"
]
],
[
[
"Measles virus vaccine live attenuated",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Bor... | Measles virus vaccine live attenuated may lead to a major life threatening interaction when taken with Bortezomib and Bortezomib may cause a minor interaction that can limit clinical effects when taken with Brigatinib
Measles virus vaccine live attenuated may lead to a major life threatening interaction when taken with... |
DB00860 | DB09043 | 891 | 135 | [
"DDInter1513",
"DDInter36"
] | Prednisolone | Albiglutide | Prednisolone is a glucocorticoid similar to [cortisol] used for its anti-inflammatory, immunosuppressive, anti-neoplastic, and vasoconstrictive effects. Prednisolone was granted FDA approval on 21 June 1955. | Albiglutide is a glucagon-like peptide-1 agonist (GLP-1) biologic drug indicated in the treatment of type 2 diabetes. It is marketed under the brands Eperzan and Tanzeum by GSK (GlaxoSmithKline). It is a dipeptidyl peptidase-4-resistant glucagon-like peptide-1 dimer fused to human albumin. Albiglutide was approved on A... | Moderate | 1 | [
[
[
891,
24,
135
]
],
[
[
891,
63,
126
],
[
126,
23,
135
]
],
[
[
891,
40,
1103
],
[
1103,
23,
135
]
],
[
[
891,
63,
323
],
[
323,
2... | [
[
[
"Prednisolone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Albiglutide"
]
],
[
[
"Prednisolone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Warfarin"
],
[... | Prednisolone may cause a moderate interaction that could exacerbate diseases when taken with Warfarin and Warfarin may cause a minor interaction that can limit clinical effects when taken with Albiglutide
Prednisolone (Compound) resembles Amcinonide (Compound) and Amcinonide may cause a minor interaction that can limit... |
DB01235 | DB11989 | 1,191 | 1,434 | [
"DDInter1054",
"DDInter183"
] | Levodopa | Benznidazole | Levodopa is a prodrug of dopamine that is administered to patients with Parkinson's due to its ability to cross the blood-brain barrier[Label]. Levodopa can be metabolised to dopamine on either side of the blood-brain barrier and so it is generally administered with a dopa decarboxylase inhibitor like carbidopa to prev... | Benznidazole was granted accelerated approval for the treatment of Chagas disease in children 2-12 years of age by the FDA on August 29, 2017. It is the first treatment made available in the United States for Chagas disease. | Moderate | 1 | [
[
[
1191,
24,
1434
]
],
[
[
1191,
24,
375
],
[
375,
24,
1434
]
],
[
[
1191,
24,
148
],
[
148,
63,
1434
]
],
[
[
1191,
63,
581
],
[
581,
... | [
[
[
"Levodopa",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Benznidazole"
]
],
[
[
"Levodopa",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Certolizumab pegol"
],
... | Levodopa may cause a moderate interaction that could exacerbate diseases when taken with Certolizumab pegol and Certolizumab pegol may cause a moderate interaction that could exacerbate diseases when taken with Benznidazole
Levodopa may cause a moderate interaction that could exacerbate diseases when taken with Secnida... |
DB01191 | DB08875 | 1,039 | 1,618 | [
"DDInter518",
"DDInter262"
] | Dexfenfluramine | Cabozantinib | Dexfenfluramine, also marketed under the name Redux, is a serotoninergic anorectic drug. For a fairly limited time during the middle of the nineties, the US FDA had approved it for use in managing weight loss. However, following multiple concerns about the cardiovascular side-effects of the drug, such approval was with... | Cabozantinib was first approved in 2012 and is a non-specific tyrosine kinase inhibitor. It was initially approved in the US under the brand name Cometriq, which is indicated for the treatment of metastatic medullary thyroid cancer. In 2016, a capsule formulation (Cabometyx) was approved for the treatment of advanced r... | Moderate | 1 | [
[
[
1039,
24,
1618
]
],
[
[
1039,
24,
1662
],
[
1662,
63,
1618
]
],
[
[
1039,
24,
170
],
[
170,
24,
1618
]
],
[
[
1039,
25,
41
],
[
41,
... | [
[
[
"Dexfenfluramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cabozantinib"
]
],
[
[
"Dexfenfluramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Picosulfuric ac... | Dexfenfluramine may cause a moderate interaction that could exacerbate diseases when taken with Picosulfuric acid and Picosulfuric acid may cause a moderate interaction that could exacerbate diseases when taken with Cabozantinib
Dexfenfluramine may cause a moderate interaction that could exacerbate diseases when taken ... |
DB00224 | DB00641 | 215 | 467 | [
"DDInter917",
"DDInter1675"
] | Indinavir | Simvastatin | A potent and specific HIV protease inhibitor that appears to have good oral bioavailability. [PubChem] | Simvastatin, also known as the brand name product Zocor, is a lipid-lowering drug derived synthetically from a fermentation product of _Aspergillus terreus_. It belongs to the statin class of medications, which are used to lower the risk of cardiovascular disease and manage abnormal lipid levels by inhibiting the endog... | Major | 2 | [
[
[
215,
25,
467
]
],
[
[
215,
6,
5912
],
[
5912,
45,
467
]
],
[
[
215,
7,
7245
],
[
7245,
46,
467
]
],
[
[
215,
18,
16641
],
[
16641,
... | [
[
[
"Indinavir",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Simvastatin"
]
],
[
[
"Indinavir",
"{u} (Compound) binds {v} (Gene)",
"ABCC2"
],
[
"ABCC2",
"{u} (Gene) is bound by {v} (Compound)",
"Simvastati... | Indinavir (Compound) binds ABCC2 (Gene) and ABCC2 (Gene) is bound by Simvastatin (Compound)
Indinavir (Compound) upregulates SSBP2 (Gene) and SSBP2 (Gene) is upregulated by Simvastatin (Compound)
Indinavir (Compound) downregulates LYPLA1 (Gene) and LYPLA1 (Gene) is downregulated by Simvastatin (Compound)
Indinavir (Com... |
DB00418 | DB00860 | 536 | 891 | [
"DDInter1650",
"DDInter1513"
] | Secobarbital | Prednisolone | Secobarbital (marketed by Eli Lilly and Company under the brand names Seconal and Tuinal) is a barbiturate derivative drug with anaesthetic, anticonvulsant, sedative and hypnotic properties. It is commonly known as quinalbarbitone in the United Kingdom. | Prednisolone is a glucocorticoid similar to [cortisol] used for its anti-inflammatory, immunosuppressive, anti-neoplastic, and vasoconstrictive effects. Prednisolone was granted FDA approval on 21 June 1955. | Moderate | 1 | [
[
[
536,
24,
891
]
],
[
[
536,
24,
175
],
[
175,
40,
891
]
],
[
[
536,
24,
1547
],
[
1547,
1,
891
]
],
[
[
536,
21,
28653
],
[
28653,
... | [
[
[
"Secobarbital",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Prednisolone"
]
],
[
[
"Secobarbital",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Triamcinolone"
],... | Secobarbital may cause a moderate interaction that could exacerbate diseases when taken with Triamcinolone and Triamcinolone (Compound) resembles Prednisolone (Compound)
Secobarbital may cause a moderate interaction that could exacerbate diseases when taken with Exemestane and Exemestane (Compound) resembles Prednisolo... |
DB01033 | DB14443 | 328 | 987 | [
"DDInter1156",
"DDInter1931"
] | Mercaptopurine | Vibrio cholerae CVD 103-HgR strain live antigen | An antimetabolite antineoplastic agent with immunosuppressant properties. It interferes with nucleic acid synthesis by inhibiting purine metabolism and is used, usually in combination with other drugs, in the treatment of or in remission maintenance programs for leukemia. | _Vibrio cholerae_ CVD 103-HgR strain live antigen is a component of Vaxchora, an oral vaccine for immunization against _Vibrio cholerae_ serogroup O1. Cholera is an acute bacterial disease of the small intestine caused by _Vibrio cholerae_, which is gram-negative bacteria. Two serogroups of _V. cholerae_, O1 and O139, ... | Moderate | 1 | [
[
[
328,
24,
987
]
],
[
[
328,
63,
141
],
[
141,
24,
987
]
],
[
[
328,
24,
1488
],
[
1488,
24,
987
]
],
[
[
328,
64,
581
],
[
581,
2... | [
[
[
"Mercaptopurine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Vibrio cholerae CVD 103-HgR strain live antigen"
]
],
[
[
"Mercaptopurine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken ... | Mercaptopurine may cause a moderate interaction that could exacerbate diseases when taken with Floxuridine and Floxuridine may cause a moderate interaction that could exacerbate diseases when taken with Vibrio cholerae CVD 103-HgR strain live antigen
Mercaptopurine may cause a moderate interaction that could exacerbate... |
DB00872 | DB01190 | 1,080 | 568 | [
"DDInter438",
"DDInter398"
] | Conivaptan | Clindamycin | Conivaptan is a non-peptide inhibitor of antidiuretic hormone (vasopressin). It was approved in 2004 for hyponatremia (low blood sodium levels) caused by syndrome of inappropriate antidiuretic hormone (SIADH). Conivaptan inhibits both isotypes of the vasopressin receptor (V1a and V2). | Clindamycin is a semi-synthetic lincosamide antibiotic used in the treatment of a variety of serious infections due to susceptible microorganisms[L11599,L11596] as well as topically for acne vulgaris. It has a relatively narrow spectrum of activity that includes anaerobic bacteria as well as gram-positive cocci and bac... | Moderate | 1 | [
[
[
1080,
24,
568
]
],
[
[
1080,
6,
8374
],
[
8374,
45,
568
]
],
[
[
1080,
21,
28803
],
[
28803,
60,
568
]
],
[
[
1080,
25,
609
],
[
609,
... | [
[
[
"Conivaptan",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Clindamycin"
]
],
[
[
"Conivaptan",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compound)"... | Conivaptan (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Clindamycin (Compound)
Conivaptan (Compound) causes Anaemia (Side Effect) and Anaemia (Side Effect) is caused by Clindamycin (Compound)
Conivaptan may lead to a major life threatening interaction when taken with Clarithromycin and Clarithromycin ma... |
DB00188 | DB01076 | 168 | 700 | [
"DDInter222",
"DDInter133"
] | Bortezomib | Atorvastatin | Bortezomib is a dipeptide boronic acid derivative and proteasome inhibitor used to treat multiple myeloma and mantle cell lymphoma. The 26S proteasome is a protein complex that degrades ubiquitinated proteins in the ubiquitin-proteasome pathway: reversible inhibition of the 26S proteasome, leading to cell cycle arrest ... | Atorvastatin (Lipitor®), is a lipid-lowering drug included in the statin class of medications. By inhibiting the endogenous production of cholesterol in the liver, statins lower abnormal cholesterol and lipid levels, and ultimately reduce the risk of cardiovascular disease. More specifically, statin medications competi... | Moderate | 1 | [
[
[
168,
24,
700
]
],
[
[
168,
24,
1080
],
[
1080,
1,
700
]
],
[
[
168,
6,
12523
],
[
12523,
45,
700
]
],
[
[
168,
7,
8155
],
[
8155,
... | [
[
[
"Bortezomib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Atorvastatin"
]
],
[
[
"Bortezomib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Conivaptan"
],
[
... | Bortezomib may cause a moderate interaction that could exacerbate diseases when taken with Conivaptan and Conivaptan (Compound) resembles Atorvastatin (Compound)
Bortezomib (Compound) binds CYP2D6 (Gene) and CYP2D6 (Gene) is bound by Atorvastatin (Compound)
Bortezomib (Compound) upregulates ABCC5 (Gene) and ABCC5 (Gene... |
DB01033 | DB09498 | 328 | 810 | [
"DDInter1156",
"DDInter1715"
] | Mercaptopurine | Strontium chloride Sr-89 | An antimetabolite antineoplastic agent with immunosuppressant properties. It interferes with nucleic acid synthesis by inhibiting purine metabolism and is used, usually in combination with other drugs, in the treatment of or in remission maintenance programs for leukemia. | Strontium chloride (Sr-89), initially FDA-approved in 1993, is used as a paliative therapeutic option to help relieve the pain from bone metastases. Strontium chloride is mainly used in cases of metastatic castrate-resistant prostate cancer. Bone metastases is a common and severe complication presented in advanced stag... | Moderate | 1 | [
[
[
328,
24,
810
]
],
[
[
328,
63,
552
],
[
552,
24,
810
]
],
[
[
328,
24,
60
],
[
60,
24,
810
]
],
[
[
328,
74,
482
],
[
482,
24,
... | [
[
[
"Mercaptopurine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Strontium chloride Sr-89"
]
],
[
[
"Mercaptopurine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Carmu... | Mercaptopurine may cause a moderate interaction that could exacerbate diseases when taken with Carmustine and Carmustine may cause a moderate interaction that could exacerbate diseases when taken with Strontium chloride Sr-89
Mercaptopurine may cause a moderate interaction that could exacerbate diseases when taken with... |
DB08882 | DB09098 | 1,281 | 98 | [
"DDInter1070",
"DDInter1700"
] | Linagliptin | Somatrem | Linagliptin is a DPP-4 inhibitor developed by Boehringer Ingelheim for the treatment of type II diabetes. Linagliptin differs from other DPP-4 inhibitors in that it has a non-linear pharmacokinetic profile, is not primarily eliminated by the renal system, and obeys concentration dependant protein binding. Linagliptin w... | Despite the ability of almost all contemporary recombinant growth hormones to cause definite and demonstrable increases in growth rate in patients who are administered the drug, the use of these agents continues to be mired in persistent bioethical debate . Such discussion revolves around whether patients' natural disp... | Moderate | 1 | [
[
[
1281,
24,
98
]
],
[
[
1281,
63,
168
],
[
168,
23,
98
]
],
[
[
1281,
63,
1671
],
[
1671,
24,
98
]
],
[
[
1281,
24,
1375
],
[
1375,
... | [
[
[
"Linagliptin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Somatrem"
]
],
[
[
"Linagliptin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bortezomib"
],
[
... | Linagliptin may cause a moderate interaction that could exacerbate diseases when taken with Bortezomib and Bortezomib may cause a minor interaction that can limit clinical effects when taken with Somatrem
Linagliptin may cause a moderate interaction that could exacerbate diseases when taken with Flibanserin and Flibans... |
DB01088 | DB11166 | 714 | 18 | [
"DDInter908",
"DDInter104"
] | Iloprost | Antithrombin Alfa | Iloprost is a mimetic of prostacyclin (PGI2; epoprostenol). Iloprost consists of a mixture of the 4R and 4S diastereoisomers at a ratio of approximately 53:47. It is a potent vasodilator with reported anti-thrombotic properties. | Antithrombin Alfa is a recombinant antithrombin , an anticoagulant, that is used for the prevention of thromboembolic events in patients that have hereditary deficiency of antithrombin in high risk situations. | Moderate | 1 | [
[
[
714,
24,
18
]
],
[
[
714,
63,
1595
],
[
1595,
24,
18
]
],
[
[
714,
24,
738
],
[
738,
63,
18
]
],
[
[
714,
24,
1039
],
[
1039,
24... | [
[
[
"Iloprost",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Antithrombin Alfa"
]
],
[
[
"Iloprost",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Collagenase clostridium ... | Iloprost may cause a moderate interaction that could exacerbate diseases when taken with Collagenase clostridium histolyticum and Collagenase clostridium histolyticum may cause a moderate interaction that could exacerbate diseases when taken with Antithrombin Alfa
Iloprost may cause a moderate interaction that could ex... |
DB00427 | DB00633 | 1,233 | 614 | [
"DDInter1879",
"DDInter520"
] | Triprolidine | Dexmedetomidine | First generation histamine H1 antagonist used in allergic rhinitis; asthma; and urticaria. It is a component of cough and cold medicines. It may cause drowsiness. | An agonist of receptors, adrenergic alpha-2 that is used in veterinary medicine for its analgesic and sedative properties. It is the racemate of dexmedetomidine. | Moderate | 1 | [
[
[
1233,
24,
614
]
],
[
[
1233,
6,
12523
],
[
12523,
45,
614
]
],
[
[
1233,
24,
222
],
[
222,
63,
614
]
],
[
[
1233,
24,
530
],
[
530,
... | [
[
[
"Triprolidine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dexmedetomidine"
]
],
[
[
"Triprolidine",
"{u} (Compound) binds {v} (Gene)",
"CYP2D6"
],
[
"CYP2D6",
"{u} (Gene) is bound by {v} (Co... | Triprolidine (Compound) binds CYP2D6 (Gene) and CYP2D6 (Gene) is bound by Dexmedetomidine (Compound)
Triprolidine may cause a moderate interaction that could exacerbate diseases when taken with Sibutramine and Sibutramine may cause a moderate interaction that could exacerbate diseases when taken with Dexmedetomidine
Tr... |
DB00461 | DB01082 | 598 | 1,448 | [
"DDInter1254",
"DDInter1713"
] | Nabumetone | Streptomycin | Nabumetone was originally developed as a non-acidic non-steroidal anti-inflammatory drug (NSAID).[label] It was thought to avoid trapping of the drug in the stomach by making it unable to dissociate into ions which was believed to reduce GI toxicity by limiting local action. While slightly reduced, possibly due to a de... | Streptomycin, an antibiotic derived from _Streptomyces griseus_, was the first aminoglycoside to be discovered and used in practice in the 1940s.[A233325,A233390] Selman Waksman and eventually Albert Schatz were recognized with the Nobel Prize in Medicine for their discovery of streptomycin and its antibacterial activi... | Moderate | 1 | [
[
[
598,
24,
1448
]
],
[
[
598,
21,
29327
],
[
29327,
60,
1448
]
],
[
[
598,
24,
1272
],
[
1272,
63,
1448
]
],
[
[
598,
24,
91
],
[
91,
... | [
[
[
"Nabumetone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Streptomycin"
]
],
[
[
"Nabumetone",
"{u} (Compound) causes {v} (Side Effect)",
"Renal failure"
],
[
"Renal failure",
"{u} (Side Effec... | Nabumetone (Compound) causes Renal failure (Side Effect) and Renal failure (Side Effect) is caused by Streptomycin (Compound)
Nabumetone may cause a moderate interaction that could exacerbate diseases when taken with Flucytosine and Flucytosine may cause a moderate interaction that could exacerbate diseases when taken ... |
DB09420 | DB11921 | 1,074 | 1,019 | [
"DDInter953",
"DDInter492"
] | Iodide I-123 | Deflazacort | Iodide I-123 (as sodium Iodide I-123) is a radioactive isotope of iodine used in nuclear medicine for the diagnostic study of thyroid disease. Following oral administration, I-123 is absorbed through the gastrointestinal tract and is taken up by the thyroid gland. After incorporation, a gamma camera is used to detect t... | Deflazacort, also known as Emflaza, is a corticosteroid prodrug used as an agent to manage Duchenne Muscular Dystrophy (DMD). It is marketed by Marathon Pharmaceuticals and was approved in February 2017 by the FDA.[L6694,FDA label] Duchenne Muscular Dystrophy is an inherited disorder resulting from mutations of the dys... | Moderate | 1 | [
[
[
1074,
24,
1019
]
],
[
[
1074,
63,
914
],
[
914,
24,
1019
]
],
[
[
1074,
24,
972
],
[
972,
63,
1019
]
],
[
[
1074,
24,
1004
],
[
1004,
... | [
[
[
"Iodide I-123",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Deflazacort"
]
],
[
[
"Iodide I-123",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Diflunisal"
],
... | Iodide I-123 may cause a moderate interaction that could exacerbate diseases when taken with Diflunisal and Diflunisal may cause a moderate interaction that could exacerbate diseases when taken with Deflazacort
Iodide I-123 may cause a moderate interaction that could exacerbate diseases when taken with Choline salicyla... |
DB00637 | DB01015 | 1,557 | 1,247 | [
"DDInter128",
"DDInter1724"
] | Astemizole | Sulfamethoxazole | Astemizole is a long-acting, non-sedating second generation antihistamine used in the treatment of allergy symptoms. It was withdrawn from market by the manufacturer in 1999 due to the potential to cause arrhythmias at high doses, especially when when taken with CYP inhibitors or grapefruit juice. | Sulfamethoxazole is a bacteriostatic sulfonamide antibiotic that interferes with folic acid synthesis in susceptible bacteria. It is generally given in combination with [trimethoprim], which inhibits a sequential step in bacterial folic acid synthesis - these agents work synergistically to block two consecutive steps i... | Minor | 0 | [
[
[
1557,
23,
1247
]
],
[
[
1557,
6,
8374
],
[
8374,
45,
1247
]
],
[
[
1557,
18,
10375
],
[
10375,
57,
1247
]
],
[
[
1557,
64,
11
],
[
11,... | [
[
[
"Astemizole",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Sulfamethoxazole"
]
],
[
[
"Astemizole",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compoun... | Astemizole (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Sulfamethoxazole (Compound)
Astemizole (Compound) downregulates RPS4Y1 (Gene) and RPS4Y1 (Gene) is downregulated by Sulfamethoxazole (Compound)
Astemizole may lead to a major life threatening interaction when taken with Toremifene and Toremifene ma... |
DB00046 | DB00436 | 1,179 | 323 | [
"DDInter940",
"DDInter179"
] | Insulin lispro | Bendroflumethiazide | Insulin lispro is a rapid-acting form of insulin used for the treatment of hyperglycemia caused by Type 1 and Type 2 Diabetes. Insulin is prescribed for the management of diabetes mellitus to mimic the activity of endogenously produced human insulin, a peptide hormone produced by beta cells of the pancreas that promote... | A thiazide diuretic with actions and uses similar to those of hydrochlorothiazide. It has been used in the treatment of familial hyperkalemia, hypertension, edema, and urinary tract disorders. (From Martindale, The Extra Pharmacopoeia, 30th ed, p810) | Moderate | 1 | [
[
[
1179,
24,
323
]
],
[
[
1179,
24,
1014
],
[
1014,
1,
323
]
],
[
[
1179,
24,
1669
],
[
1669,
62,
323
]
],
[
[
1179,
24,
964
],
[
964,
... | [
[
[
"Insulin lispro",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bendroflumethiazide"
]
],
[
[
"Insulin lispro",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Benzthiazi... | Insulin lispro may cause a moderate interaction that could exacerbate diseases when taken with Benzthiazide and Benzthiazide (Compound) resembles Bendroflumethiazide (Compound)
Insulin lispro may cause a moderate interaction that could exacerbate diseases when taken with Minocycline and Minocycline may cause a minor in... |
DB00701 | DB01309 | 1,091 | 1,254 | [
"DDInter90",
"DDInter933"
] | Amprenavir | Insulin glulisine | Amprenavir is a protease inhibitor used to treat HIV infection. | Insulin glulisine is a short-acting form of insulin used for the treatment of hyperglycemia caused by Type 1 and Type 2 Diabetes. Insulin is typically prescribed for the management of diabetes mellitus to mimic the activity of endogenously produced human insulin, a peptide hormone produced by beta cells of the pancreas... | Moderate | 1 | [
[
[
1091,
24,
1254
]
],
[
[
1091,
63,
1424
],
[
1424,
24,
1254
]
],
[
[
1091,
24,
167
],
[
167,
24,
1254
]
],
[
[
1091,
24,
1450
],
[
1450... | [
[
[
"Amprenavir",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Insulin glulisine"
]
],
[
[
"Amprenavir",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Quinine"
],
... | Amprenavir may cause a moderate interaction that could exacerbate diseases when taken with Quinine and Quinine may cause a moderate interaction that could exacerbate diseases when taken with Insulin glulisine
Amprenavir may cause a moderate interaction that could exacerbate diseases when taken with Hydrocortisone and H... |
DB08820 | DB14840 | 1,478 | 861 | [
"DDInter997",
"DDInter1601"
] | Ivacaftor | Ripretinib | Ivacaftor (also known as Kalydeco or VX-770) is a drug used for the management of Cystic Fibrosis (CF). It is manufactured and distributed by Vertex Pharmaceuticals. It was approved by the Food and Drug Administration on January 31, 2012, and by Health Canada in late 2012. Ivacaftor is administered as a monotherapy and... | Ripretinib is a kinase inhibitor used for the treatment of advanced gastrointestinal stromal tumor (GIST) that has not adequately responded to other kinase inhibitors such as [sunitinib] and [imatinib]. Ripretinib, also known as Qinlock, is manufactured by Deciphera Pharmaceuticals and was initially approved by the FDA... | Moderate | 1 | [
[
[
1478,
24,
861
]
],
[
[
1478,
25,
351
],
[
351,
24,
861
]
],
[
[
1478,
24,
214
],
[
214,
24,
861
]
],
[
[
1478,
63,
353
],
[
353,
... | [
[
[
"Ivacaftor",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ripretinib"
]
],
[
[
"Ivacaftor",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Ribociclib"
],
[
"Ribociclib",... | Ivacaftor may lead to a major life threatening interaction when taken with Ribociclib and Ribociclib may cause a moderate interaction that could exacerbate diseases when taken with Ripretinib
Ivacaftor may cause a moderate interaction that could exacerbate diseases when taken with Fostamatinib and Fostamatinib may caus... |
DB00969 | DB11837 | 2 | 1,297 | [
"DDInter52",
"DDInter1351"
] | Alosetron | Osilodrostat | Alosetron is a 5-HT3 antagonist used only for the management of severe diarrhoea-predominant irritable bowel syndrome (IBS) in women. Alosetron has an antagonist action on the 5-HT3 receptors and thus may modulate serotonin-sensitive gastrointestinal (GI) processes. Alosetron was voluntarily withdrawn from the US marke... | Osilodrostat is an inhibitor of 11β-hydroxylase (also referred to as CYP11B1), the enzyme that catalyzes the final step in the biosynthesis of endogenous cortisol. It is used to lower circulating cortisol levels in the treatment of Cushing's disease, a disorder in which cortisol levels are chronically and supraphysiolo... | Moderate | 1 | [
[
[
2,
24,
1297
]
],
[
[
2,
63,
1288
],
[
1288,
24,
1297
]
],
[
[
2,
24,
1520
],
[
1520,
24,
1297
]
],
[
[
2,
64,
529
],
[
529,
24,
... | [
[
[
"Alosetron",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Osilodrostat"
]
],
[
[
"Alosetron",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Zileuton"
],
[
... | Alosetron may cause a moderate interaction that could exacerbate diseases when taken with Zileuton and Zileuton may cause a moderate interaction that could exacerbate diseases when taken with Osilodrostat
Alosetron may cause a moderate interaction that could exacerbate diseases when taken with Primaquine and Primaquine... |
DB00104 | DB08815 | 966 | 154 | [
"DDInter1323",
"DDInter1104"
] | Octreotide | Lurasidone | Acromegaly is a disorder caused by excess growth hormone (GH), increasing the growth of body tissues and causing metabolic dysfunction. In most cases, it results from an anterior pituitary growth hormone-releasing tumor. Typically, the feet, hands, and face grow abnormally large; organomegaly and insulin resistance may... | Lurasidone is an atypical antipsychotic developed by Dainippon Sumitomo Pharma. It was approved by the U.S. Food and Drug Administration (FDA) for treatment of schizophrenia on October 29, 2010 and is currently pending approval for the treatment of bipolar disorder in the United States. | Moderate | 1 | [
[
[
966,
24,
154
]
],
[
[
966,
21,
29402
],
[
29402,
60,
154
]
],
[
[
966,
24,
959
],
[
959,
24,
154
]
],
[
[
966,
24,
1385
],
[
1385,
... | [
[
[
"Octreotide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lurasidone"
]
],
[
[
"Octreotide",
"{u} (Compound) causes {v} (Side Effect)",
"Hepatobiliary disease"
],
[
"Hepatobiliary disease",
"{... | Octreotide (Compound) causes Hepatobiliary disease (Side Effect) and Hepatobiliary disease (Side Effect) is caused by Lurasidone (Compound)
Octreotide may cause a moderate interaction that could exacerbate diseases when taken with Glipizide and Glipizide may cause a moderate interaction that could exacerbate diseases w... |
DB08901 | DB12240 | 1,468 | 110 | [
"DDInter1492",
"DDInter1485"
] | Ponatinib | Polatuzumab vedotin | Ponatinib is a novel Bcr-Abl tyrosine kinase inhibitor that is especially effective against the T315I mutation for the treatment of chronic myeloid leukemia. FDA approved on December 14, 2012. | Polatuzumab vedotin is a CD79b-directed antibody-drug conjugate that delivers monomethyl auristatin E (MMAE), an anti-mitotic agent, to cancer cells. The drug consists of three components - a humanized immunoglobulin G1 (IgG1) monoclonal antibody specific for human CD79b (polatuzumab), MMAE, and protease-cleavable link... | Moderate | 1 | [
[
[
1468,
24,
110
]
],
[
[
1468,
63,
129
],
[
129,
23,
110
]
],
[
[
1468,
24,
913
],
[
913,
23,
110
]
],
[
[
1468,
63,
467
],
[
467,
... | [
[
[
"Ponatinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Polatuzumab vedotin"
]
],
[
[
"Ponatinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Enzalutamide"
],... | Ponatinib may cause a moderate interaction that could exacerbate diseases when taken with Enzalutamide and Enzalutamide may cause a minor interaction that can limit clinical effects when taken with Polatuzumab vedotin
Ponatinib may cause a moderate interaction that could exacerbate diseases when taken with Apalutamide ... |
DB00241 | DB09054 | 288 | 384 | [
"DDInter257",
"DDInter905"
] | Butalbital | Idelalisib | Butalbital, or 5-allyl-5-isobutylbarbituric acid, is a derivative of barbituric acid which the hydrogens at position 5 are substituted by an allyl group and an isobutyl group. It is a short-to-intermediate acting member of barbiturates that exhibit muscle-relaxing and anti-anxiety properties that produce central nervou... | Idelalisib is a phosphoinositide 3-kinase inhibitor indicated in the treatment of chronic lymphocytic leukemia (CLL), relapsed follicular B-cell non-Hodgkin lymphoma (FL), and relapsed small lymphocytic lymphoma (SLL). For the treatment of relapsed CLL, it is currently indicated as a second-line agent in combination wi... | Moderate | 1 | [
[
[
288,
24,
384
]
],
[
[
288,
24,
222
],
[
222,
23,
384
]
],
[
[
288,
24,
1618
],
[
1618,
24,
384
]
],
[
[
288,
40,
1023
],
[
1023,
... | [
[
[
"Butalbital",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Idelalisib"
]
],
[
[
"Butalbital",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sibutramine"
],
[
... | Butalbital may cause a moderate interaction that could exacerbate diseases when taken with Sibutramine and Sibutramine may cause a minor interaction that can limit clinical effects when taken with Idelalisib
Butalbital may cause a moderate interaction that could exacerbate diseases when taken with Cabozantinib and Cabo... |
DB00530 | DB09481 | 1,195 | 460 | [
"DDInter667",
"DDInter1113"
] | Erlotinib | Magnesium carbonate | Erlotinib is an inhibitor of the epidermal growth factor receptor (EGFR) tyrosine kinase that is used in the treatment of non-small cell lung cancer, pancreatic cancer and several other types of cancer. It is typically marketed under the trade name Tarceva. Erlotinib binds to the epidermal growth factor receptor (EGFR)... | Magnesium carbonate, also known as magnesite, is a common over the counter remedy for heartburn and upset stomach caused by overproduction of acid in the stomach [FDA Label]. | Moderate | 1 | [
[
[
1195,
24,
460
]
],
[
[
1195,
63,
752
],
[
752,
23,
460
]
],
[
[
1195,
24,
1127
],
[
1127,
23,
460
]
],
[
[
1195,
24,
1213
],
[
1213,
... | [
[
[
"Erlotinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Magnesium carbonate"
]
],
[
[
"Erlotinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cimetidine"
],
... | Erlotinib may cause a moderate interaction that could exacerbate diseases when taken with Cimetidine and Cimetidine may cause a minor interaction that can limit clinical effects when taken with Magnesium carbonate
Erlotinib may cause a moderate interaction that could exacerbate diseases when taken with Nizatidine and N... |
DB00443 | DB00872 | 251 | 1,080 | [
"DDInter195",
"DDInter438"
] | Betamethasone | Conivaptan | Betamethasone is a long-acting corticosteroid with immunosuppressive and antiinflammatory properties. It can be used topically to manage inflammatory skin conditions such as eczema, and parenterally to manage several disease states including autoimmune disorders. Betamethasone has potent glucocorticoid activity and neg... | Conivaptan is a non-peptide inhibitor of antidiuretic hormone (vasopressin). It was approved in 2004 for hyponatremia (low blood sodium levels) caused by syndrome of inappropriate antidiuretic hormone (SIADH). Conivaptan inhibits both isotypes of the vasopressin receptor (V1a and V2). | Moderate | 1 | [
[
[
251,
24,
1080
]
],
[
[
251,
6,
8374
],
[
8374,
45,
1080
]
],
[
[
251,
21,
28769
],
[
28769,
60,
1080
]
],
[
[
251,
24,
126
],
[
126,
... | [
[
[
"Betamethasone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Conivaptan"
]
],
[
[
"Betamethasone",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compo... | Betamethasone (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Conivaptan (Compound)
Betamethasone (Compound) causes Feeling abnormal (Side Effect) and Feeling abnormal (Side Effect) is caused by Conivaptan (Compound)
Betamethasone may cause a moderate interaction that could exacerbate diseases when taken w... |
DB00500 | DB01250 | 24 | 712 | [
"DDInter1831",
"DDInter1334"
] | Tolmetin | Olsalazine | A non-steroidal anti-inflammatory agent (anti-inflammatory agents, NON-steroidal) similar in mode of action to indomethacin. | Olsalazine is an aminosalicylate and a prodrug of [mesalamine] (5-aminosalicylic acid, 5-ASA). It was first developed for delivering mesalamine to the colon without the use of [sulfapyridine]. Olsalazine comprises two mesalamine molecules joined by an azo bridge, which is cleaved in the colon. Olsalazine is an anti-inf... | Moderate | 1 | [
[
[
24,
24,
712
]
],
[
[
24,
24,
50
],
[
50,
40,
712
]
],
[
[
24,
6,
10522
],
[
10522,
45,
712
]
],
[
[
24,
25,
126
],
[
126,
23,
... | [
[
[
"Tolmetin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Olsalazine"
]
],
[
[
"Tolmetin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sulfasalazine"
],
[
... | Tolmetin may cause a moderate interaction that could exacerbate diseases when taken with Sulfasalazine and Sulfasalazine (Compound) resembles Olsalazine (Compound)
Tolmetin (Compound) binds PTGS1 (Gene) and PTGS1 (Gene) is bound by Olsalazine (Compound)
Tolmetin may lead to a major life threatening interaction when tak... |
DB00067 | DB00694 | 317 | 51 | [
"DDInter1921",
"DDInter485"
] | Vasopressin | Daunorubicin | Vasopressin (arginine-vasopressin or antidiuretic hormone) is a nonapeptide primarily produced in the hypothalamus that exhibits diverse physiological functions related to diuresis, hemodynamic modulation, and behaviour.[A110, A111, A112, A113, A228008] Vasopressin is very similar to oxytocin, differing in the third an... | A very toxic anthracycline aminoglycoside antineoplastic isolated from Streptomyces peucetius and others, used in treatment of leukemia and other neoplasms. | Moderate | 1 | [
[
[
317,
24,
51
]
],
[
[
317,
23,
112
],
[
112,
62,
51
]
],
[
[
317,
24,
134
],
[
134,
24,
51
]
],
[
[
317,
24,
477
],
[
477,
63,
... | [
[
[
"Vasopressin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Daunorubicin"
]
],
[
[
"Vasopressin",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Metronidazole"
],
... | Vasopressin may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Daunorubicin
Vasopressin may cause a moderate interaction that could exacerbate diseases when taken with Vinorelbine and... |
DB01174 | DB06410 | 697 | 1,196 | [
"DDInter1442",
"DDInter595"
] | Phenobarbital | Doxercalciferol | A barbituric acid derivative that acts as a nonselective central nervous system depressant. It promotes binding to inhibitory gamma-aminobutyric acid subtype receptors, and modulates chloride currents through receptor channels. It also inhibits glutamate induced depolarizations. | Doxercalciferol is a synthetic vitamin D2 analog that undergoes metabolic activation in vivo to form 1α,25-dihydroxyvitamin D2 (1α,25-(OH)2D2), a naturally occurring, biologically active form of vitamin D2. Doxercalciferol is indicated for the treatment of secondary hyperparathyroidism in patients with chronic kidney d... | Moderate | 1 | [
[
[
697,
24,
1196
]
],
[
[
697,
40,
362
],
[
362,
24,
1196
]
],
[
[
697,
24,
1619
],
[
1619,
63,
1196
]
],
[
[
697,
25,
1017
],
[
1017,
... | [
[
[
"Phenobarbital",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Doxercalciferol"
]
],
[
[
"Phenobarbital",
"{u} (Compound) resembles {v} (Compound)",
"Phenytoin"
],
[
"Phenytoin",
"{u} may cause ... | Phenobarbital (Compound) resembles Phenytoin (Compound) and Phenytoin may cause a moderate interaction that could exacerbate diseases when taken with Doxercalciferol
Phenobarbital may cause a moderate interaction that could exacerbate diseases when taken with Rucaparib and Rucaparib may cause a moderate interaction tha... |
DB01118 | DB01128 | 33 | 918 | [
"DDInter76",
"DDInter204"
] | Amiodarone | Bicalutamide | Amiodarone is a benzofuran derivative, anti-arrhythmic drug used commonly in a variety of settings. Most known for its approved indication in life-threatening ventricular arrhythmias, it is also used off-label in the outpatient and inpatient setting for atrial fibrillation. Because of its ability to cause serious toxic... | Bicalutamide is an oral non-steroidal anti-androgen for prostate cancer. It is comprised of a racemic mixture that is a 50:50 composition of the (R)-bicalutamide and (S)-bicalutamide enantionmers. Bicalutamide binds to the androgen receptor. | Major | 2 | [
[
[
33,
25,
918
]
],
[
[
33,
25,
129
],
[
129,
40,
918
]
],
[
[
33,
6,
8374
],
[
8374,
45,
918
]
],
[
[
33,
21,
28642
],
[
28642,
60... | [
[
[
"Amiodarone",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Bicalutamide"
]
],
[
[
"Amiodarone",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Enzalutamide"
],
[
"Enzalutamide",
... | Amiodarone may lead to a major life threatening interaction when taken with Enzalutamide and Enzalutamide (Compound) resembles Bicalutamide (Compound)
Amiodarone (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Bicalutamide (Compound)
Amiodarone (Compound) causes Shock (Side Effect) and Shock (Side Effect) ... |
DB00041 | DB00348 | 1,648 | 254 | [
"DDInter38",
"DDInter1300"
] | Aldesleukin | Nitisinone | Aldesleukin, a lymphokine, is produced by recombinant DNA technology using a genetically engineered E. coli strain containing an analog of the human interleukin-2 gene. Genetic engineering techniques were used to modify the human IL-2 gene, and the resulting expression clone encodes a modified human interleukin-2. This... | Nitisinone is a synthetic reversible inhibitor of 4-hydroxyphenylpyruvate dioxygenase. It is used in the treatment of hereditary tyrosinemia type 1. It is sold under the brand name Orfadin. | Moderate | 1 | [
[
[
1648,
24,
254
]
],
[
[
1648,
24,
288
],
[
288,
24,
254
]
],
[
[
1648,
24,
1220
],
[
1220,
63,
254
]
],
[
[
1648,
25,
990
],
[
990,
... | [
[
[
"Aldesleukin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Nitisinone"
]
],
[
[
"Aldesleukin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Butalbital"
],
[
... | Aldesleukin may cause a moderate interaction that could exacerbate diseases when taken with Butalbital and Butalbital may cause a moderate interaction that could exacerbate diseases when taken with Nitisinone
Aldesleukin may cause a moderate interaction that could exacerbate diseases when taken with Dexamethasone and D... |
DB01577 | DB09082 | 1,529 | 659 | [
"DDInter1161",
"DDInter1934"
] | Metamfetamine | Vilanterol | Metamfetamine (methamphetamine) is a psychostimulant and sympathomimetic drug, and a member of the amphetamine group of sympathomimetic amines. Methamphetamine can induce effects such as euphoria, increased alertness and energy, and enhanced self-esteem. It is a scheduled drug in most countries due to its high potentia... | Vilanterol is a selective long-acting β2-adrenergic agonist (LABA) with inherent 24-hour activity for the once-daily treatment of COPD and asthma. This is in response to the need for longer-acting β2-adrenergic agonists to overcome poor patient compliance (due to the frequency of dosing regimens or complexities of drug... | Moderate | 1 | [
[
[
1529,
24,
659
]
],
[
[
1529,
24,
1296
],
[
1296,
63,
659
]
],
[
[
1529,
1,
1161
],
[
1161,
24,
659
]
],
[
[
1529,
24,
1450
],
[
1450,
... | [
[
[
"Metamfetamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Vilanterol"
]
],
[
[
"Metamfetamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Insulin degludec"
... | Metamfetamine may cause a moderate interaction that could exacerbate diseases when taken with Insulin degludec and Insulin degludec may cause a moderate interaction that could exacerbate diseases when taken with Vilanterol
Metamfetamine (Compound) resembles Selegiline (Compound) and Selegiline may cause a moderate inte... |
DB00067 | DB09082 | 317 | 659 | [
"DDInter1921",
"DDInter1934"
] | Vasopressin | Vilanterol | Vasopressin (arginine-vasopressin or antidiuretic hormone) is a nonapeptide primarily produced in the hypothalamus that exhibits diverse physiological functions related to diuresis, hemodynamic modulation, and behaviour.[A110, A111, A112, A113, A228008] Vasopressin is very similar to oxytocin, differing in the third an... | Vilanterol is a selective long-acting β2-adrenergic agonist (LABA) with inherent 24-hour activity for the once-daily treatment of COPD and asthma. This is in response to the need for longer-acting β2-adrenergic agonists to overcome poor patient compliance (due to the frequency of dosing regimens or complexities of drug... | Moderate | 1 | [
[
[
317,
24,
659
]
],
[
[
317,
24,
870
],
[
870,
23,
659
]
],
[
[
317,
24,
927
],
[
927,
63,
659
]
],
[
[
317,
25,
1069
],
[
1069,
2... | [
[
[
"Vasopressin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Vilanterol"
]
],
[
[
"Vasopressin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fludrocortisone"
],
... | Vasopressin may cause a moderate interaction that could exacerbate diseases when taken with Fludrocortisone and Fludrocortisone may cause a minor interaction that can limit clinical effects when taken with Vilanterol
Vasopressin may cause a moderate interaction that could exacerbate diseases when taken with Encorafenib... |
DB00015 | DB00533 | 582 | 1,416 | [
"DDInter1585",
"DDInter1613"
] | Reteplase | Rofecoxib | Human tissue plasminogen activator, purified, glycosylated, 355 residues purified from CHO cells. Retavase is considered a "third-generation" thrombolytic agent, genetically engineered to retain and delete certain portions of human tPA. Retavase is a deletion mutein of human tPA formed by deleting various amino acids p... | Rofecoxib is used for the treatment of osteoarthritis, rheumatoid arthritis, acute pain in adults, and primary dysmenorrhea, as well as acute treatment of migraine attacks with or without auras. Rofecoxib is a solid. This compound belongs to the stilbenes. These are organic compounds containing a 1,2-diphenylethylene m... | Moderate | 1 | [
[
[
582,
24,
1416
]
],
[
[
582,
25,
1409
],
[
1409,
63,
1416
]
],
[
[
582,
64,
1578
],
[
1578,
24,
1416
]
],
[
[
582,
24,
714
],
[
714,
... | [
[
[
"Reteplase",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Rofecoxib"
]
],
[
[
"Reteplase",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Apixaban"
],
[
"Apixaban",
... | Reteplase may lead to a major life threatening interaction when taken with Apixaban and Apixaban may cause a moderate interaction that could exacerbate diseases when taken with Rofecoxib
Reteplase may lead to a major life threatening interaction when taken with Lepirudin and Lepirudin may cause a moderate interaction t... |
DB08881 | DB12674 | 868 | 975 | [
"DDInter1925",
"DDInter1105"
] | Vemurafenib | Lurbinectedin | Vemurafenib is a competitive kinase inhibitor with activity against BRAF kinase with mutations like V600E. It exerts its function by binding to the ATP-binding domain of the mutant BRAF. Vemurafenib was co-developed by Roche and Plexxikon and it obtained its FDA approval on August 17, 2011, under the company Hoffmann L... | Lurbinectedin is a DNA alkylating agent that has been investigated in the treatment of a variety of cancers, including mesothelioma, chronic lymphocytic leukemia (CLL), breast cancer, and small-cell lung cancer (SCLC). It is a derivative of the marine-derived agent ecteinascidin ([trabectedin]), an anticancer agent fou... | Moderate | 1 | [
[
[
868,
24,
975
]
],
[
[
868,
24,
1613
],
[
1613,
24,
975
]
],
[
[
868,
24,
159
],
[
159,
63,
975
]
],
[
[
868,
63,
372
],
[
372,
2... | [
[
[
"Vemurafenib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lurbinectedin"
]
],
[
[
"Vemurafenib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Peginterferon beta-1a"... | Vemurafenib may cause a moderate interaction that could exacerbate diseases when taken with Peginterferon beta-1a and Peginterferon beta-1a may cause a moderate interaction that could exacerbate diseases when taken with Lurbinectedin
Vemurafenib may cause a moderate interaction that could exacerbate diseases when taken... |
DB06402 | DB11730 | 1,079 | 351 | [
"DDInter1756",
"DDInter1588"
] | Telavancin | Ribociclib | Telavancin is a semi-synthetic derivative of vanocymycin that has bactericidal activity against Methicillin-resistant Staphylococcus aureus (MRSA) and other gram-positive bacteria. MRSA is an important pathogen capable of causing hospital-acquired pneumonia (HAP), ventilator-associated pneumonia (VAP), and skin and sub... | Ribociclib is a selective cyclin-dependent kinase inhibitor, a class of drugs that help slow the progression of cancer by inhibiting two proteins called cyclin-dependent kinase 4 and 6 (CDK4/6). These proteins, when over-activated, can enable cancer cells to grow and divide too quickly. Targeting CDK4/6 with enhanced p... | Major | 2 | [
[
[
1079,
25,
351
]
],
[
[
1079,
62,
112
],
[
112,
23,
351
]
],
[
[
1079,
63,
355
],
[
355,
24,
351
]
],
[
[
1079,
24,
1491
],
[
1491,
... | [
[
[
"Telavancin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Ribociclib"
]
],
[
[
"Telavancin",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Metronidazole"
],
[
"Metronida... | Telavancin may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Ribociclib
Telavancin may cause a moderate interaction that could exacerbate diseases when taken with Lactulose and Lactu... |
DB00674 | DB08871 | 1,516 | 36 | [
"DDInter802",
"DDInter666"
] | Galantamine | Eribulin | Galantamine is a tertiary alkaloid and reversible, competitive inhibitor of the acetylcholinesterase (AChE) enzyme, which is a widely studied therapeutic target used in the treatment of Alzheimer's disease. First characterized in the early 1950s, galantamine is a tertiary alkaloid that was extracted from botanical sour... | Eribulin is a microtubule inhibitor indicated for the treatment of patients with metastatic breast cancer who have previously received at least two chemotherapeutic regimens for the treatment of metastatic disease. Eribulin was isolated from the marine sponge Halichondria okadai. Eribulin is also being investigated for... | Moderate | 1 | [
[
[
1516,
24,
36
]
],
[
[
1516,
63,
1424
],
[
1424,
24,
36
]
],
[
[
1516,
24,
820
],
[
820,
24,
36
]
],
[
[
1516,
24,
384
],
[
384,
... | [
[
[
"Galantamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Eribulin"
]
],
[
[
"Galantamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Quinine"
],
[
... | Galantamine may cause a moderate interaction that could exacerbate diseases when taken with Quinine and Quinine may cause a moderate interaction that could exacerbate diseases when taken with Eribulin
Galantamine may cause a moderate interaction that could exacerbate diseases when taken with Alimemazine and Alimemazine... |
DB01240 | DB04835 | 885 | 1,655 | [
"DDInter657",
"DDInter1125"
] | Epoprostenol | Maraviroc | A prostaglandin that is a powerful vasodilator and inhibits platelet aggregation. It is biosynthesized enzymatically from prostaglandin endoperoxides in human vascular tissue. The sodium salt has been also used to treat primary pulmonary hypertension. | Maraviroc (brand-named Selzentry, or Celsentri outside the U.S.) is a chemokine receptor antagonist drug developed by the drug company Pfizer that is designed to act against HIV by interfering with the interaction between HIV and CCR5. It was originally labelled as UK-427857 during development but was assigned the Mara... | Moderate | 1 | [
[
[
885,
24,
1655
]
],
[
[
885,
21,
28792
],
[
28792,
60,
1655
]
],
[
[
885,
63,
1214
],
[
1214,
24,
1655
]
],
[
[
885,
40,
1061
],
[
1061... | [
[
[
"Epoprostenol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Maraviroc"
]
],
[
[
"Epoprostenol",
"{u} (Compound) causes {v} (Side Effect)",
"Gastrointestinal disorder"
],
[
"Gastrointestinal disorder... | Epoprostenol (Compound) causes Gastrointestinal disorder (Side Effect) and Gastrointestinal disorder (Side Effect) is caused by Maraviroc (Compound)
Epoprostenol may cause a moderate interaction that could exacerbate diseases when taken with Minoxidil and Minoxidil may cause a moderate interaction that could exacerbate... |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.